5-Fluorouracil
Clinical Trials Overview
778 trials found
About 5-Fluorouracil
5-Fluorouracil (5-FU) is a fluoropyrimidine antimetabolite chemotherapy agent that serves as a backbone treatment for colorectal cancer across multiple settings including adjuvant, neoadjuvant, and metastatic disease. It is commonly administered as part of combination regimens such as FOLFOX (5-FU, leucovorin, oxaliplatin) and FOLFIRI (5-FU, leucovorin, irinotecan) for both resectable and advanced colorectal cancer. The drug's efficacy can be influenced by microsatellite instability status and requires careful dosing considerations based on DPYD gene polymorphisms to prevent severe toxicity. 5-FU remains a cornerstone of colorectal cancer chemotherapy and is frequently combined with targeted agents like bevacizumab or cetuximab in metastatic settings.
Category
Chemotherapy
Brand Name
Adrucil, Carac, Efudex, Fluoroplex
Mechanism
5-Fluorouracil acts as a pyrimidine analog that interferes with DNA and RNA synthesis through multiple pathways. The drug is converted intracellularly to active metabolites including 5-fluoro-dUMP, which irreversibly inhibits thymidylate synthase, blocking the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate and thereby preventing DNA synthesis. Additional metabolites incorporate into RNA, disrupting RNA processing and protein synthesis, ultimately leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Efficacy Data by Mutation
Response rates and survival outcomes by patient molecular profile
All FOLFOX (5-FU+Oxaliplatino)
1A
48%
ORR
8.7m
PFS
19.5m
OS
n=2246
Sample
All FOLFIRI (5-FU+Irinotecan)
1A
44%
ORR
7.6m
PFS
17.4m
OS
n=2246
Sample
KRAS Backbone FOLFOX/FOLFIRI
1A
42%
ORR
8m
PFS
18.5m
OS
n=800
Sample
All Capecitabina (pro-fármaco oral)
1A
19%
ORR
4.6m
PFS
12.9m
OS
n=602
Sample
All Agente único
1A
15%
ORR
3.5m
PFS
11m
OS
n=1500
Sample
BRAF Backbone (mal pronóstico)
2A
20%
ORR
5.5m
PFS
11.7m
OS
n=200
Sample
778
Total Trials
151
Recruiting
84
Active
497
Completed
201,544
Total Enrollment
87
Countries
Research trend for 5-Fluorouracil
Number of trials started per year
Research grew, peaking at 55 trials in 2025.
Active sites for 5-Fluorouracil
Recruiting sites
87 countries
Phase:
NCT06783491
Phase 3
Recruiting
1,083 patients
The main objective of this randomized and controlled trial is to determine whether the use of a proactive strategy, systemic neoadjuvant treatment (FOLFOX) with or without hyperthermic intraperitoneal chemoterapy (HIPEC) with mitomycin C followed by ...
Spain
NCT07500298
Phase 1
Recruiting
41 patients
To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.
United States
NCT06197425
Phase 3
Recruiting
1,660 patients
Phase III multicentric, open-label, randomized study
The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment (surgery + chemotherap...
France
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031
Phase 2
Recruiting
170 patients
Medications:
5-Fluorouracil
Adagrasib
Cetuximab
Docetaxel
Irinotecan
Leucovorin
Oxaliplatin
Pembrolizumab
Pemetrexed
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients...
United States, Australia, Belgium, Canada, France, Germany, Greece, Israel, Italy, Netherlands, Port
NCT07446322
Phase 2
Recruiting
60 patients
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxalipla...
United States
NCT07412613
Phase 3
Recruiting
386 patients
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and s...
China
NCT07176182
Phase 2
Recruiting
236 patients
This study is a prospective, multicenter, open-label, randomized controlled Phase II clinical trial enrolling patients with locally advanced rectal cancer who tested positive for YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase-activating p...
China
NCT07284849
Phase 3
Recruiting
700 patients
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Georgia, Ger
NCT07283939
Not Applicable
Recruiting
420 patients
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
United States, Puerto Rico
NCT07328087
Early Phase 1
Recruiting
12 patients
This is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide vaccine, administered in com...
Greece
NCT07221357
Phase 2
Recruiting
990 patients
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cance...
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France
NCT07318805
Phase 1
Recruiting
260 patients
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to f...
United States
NCT07277270
Phase 1
Recruiting
84 patients
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safet...
United States, Australia, Spain
NCT06948448
Phase 2
Recruiting
144 patients
The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.
United States, Canada, France, Italy, Japan, Spain
NCT07389265
Phase 3
Recruiting
480 patients
The goal of this Phase 3 clinical trial is to evaluate whether continuing cetuximab treatment beyond first-line progression can improve outcomes in patients with metastatic colorectal cancer whose tumors are RAS and BRAF wild-type. The study will com...
Italy, Spain
NCT07011576
Phase 2
Recruiting
60 patients
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of thi...
United States
NCT07106034
Phase 2
Recruiting
32 patients
The ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment combined with Ongericim...
China
NCT07158164
Phase 4
Recruiting
100 patients
Medications:
5-Fluorouracil
Capecitabine
To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant pa...
United States
NCT06867822
Phase 1
Recruiting
27 patients
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with 5-fluorouracil, irinotecan (FOLFIRI) and bevacizumab for untreated advanced/metastatic CRC....
United States
NCT06997497
Phase 3
Recruiting
477 patients
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
Standard (or usual) treatments for this type of colorectal cancer may include mFOL...
United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Finland, France, German
NCT07309289
Phase 3
Recruiting
144 patients
To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
China
NCT06501482
Phase 3
Recruiting
254 patients
Eligible patients are patients with contraindication to preoperative oxaliplatin based-chemotherapy who underwent resection of no more than 10 colorectal liver metastases after preoperative FOLFIRI based chemotherapy with or without targeted agents. ...
France
NCT06696768
Phase 1
Recruiting
24 patients
This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (pri...
United States
NCT06719362
Phase 1
Recruiting
110 patients
Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with me...
United States
NCT07150247
Phase 2
Recruiting
20 patients
The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The main questions it ...
China
NCT06907342
Phase 2
Recruiting
148 patients
COSENSE-1 is an unblinded, phase II, single-armed, single center feasibility study for using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens, for male and female participants aged 18 ...
Norway
NCT06780787
Phase 2
Recruiting
26 patients
This phase II trial tests how well fluorouracil, oxaliplatin and leucovorin calcium (folinic acid) (FOLFOX) with botensilimab and balstilimab given before surgery (neoadjuvant) works in treating patients with rectal adenocarcinoma that has not spread...
United States
NCT07391618
Phase 2
Recruiting
583 patients
Phase II study of simultaneous infusion of levozolinate for injection and 5-FU as first-line treatment for advanced colorectal cancer
China
NCT07204574
Phase 1
Recruiting
40 patients
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Co...
Taiwan
NCT06887218
Phase 2
Recruiting
57 patients
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.
Patients will be randomly assigned in a 2:1...
United States
NCT03401294
Phase 2
Recruiting
32 patients
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patient...
Canada
NCT06820463
Phase 2
Recruiting
390 patients
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with ...
United States, Australia, Austria, Brazil, Czechia, France, Greece, Israel, Japan, Puerto Rico, Spai
NCT06654037
Phase 1
Recruiting
39 patients
Medications:
5-Fluorouracil
Abemaciclib
This phase I trial tests the safety, side effects, and best dose of abemaciclib in combination with 5-fluorouracil and how well it works in treating patients with colorectal cancer that has spread from where it first started (primary site) to other p...
United States
NCT07543744
Phase 1
Recruiting
180 patients
The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous administration to patients wit...
Russia
NCT06908031
Phase 2
Recruiting
49 patients
To explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospectiv...
China
NCT07562490
Phase 2
Recruiting
100 patients
Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX/CAPOX for 6 months) or the intervention group (FOLFOX/CAPOX plus bevacizumab for 6 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) ...
China
NCT06657144
Phase 1
Recruiting
154 patients
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
United States, Taiwan
NCT06917079
Phase 1
Recruiting
665 patients
Medications:
5-Fluorouracil
BBO-10203
BBO-11818
Cetuximab
Gemcitabine
Irinotecan
Leucovorin
Nab-Paclitaxel
Oxaliplatin
Pembrolizumab
Pemetrexed
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
United States, Australia
NCT06792695
Phase 2
Recruiting
120 patients
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
United States, Australia, Canada, China, France, Germany, Italy, Netherlands, South Korea, Spain, Ta
NCT06928584
Phase 2
Recruiting
221 patients
TORCH-R2 is a prospective, multicenter, randomized, phase II clinical trial. Patients aged 18 years or older with pelvic recurrence rectal cancer without synchronous distant metastases or recent chemo- and/or radiotherapy treatment, Eastern Cooperati...
China
NCT06728072
Phase 2
Recruiting
97 patients
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
United States
NCT06835569
Phase 1
Recruiting
448 patients
Medications:
5-Fluorouracil
ALTA3263
Cetuximab
Gnp
Irinotecan
Leucovorin
Midazolam
Oxaliplatin
Pembrolizumab
Pemetrexed
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
United States
NCT06978400
Phase 2
Recruiting
64 patients
The purpose of this study is to evaluate the efficacy and toxicity of FOLFOX regimen with dabrafenib and cetuximab/panitumumab in the first line of therapy for the potential treatment of colorectal cancer that: has a metastatic, inoperable; has a mut...
Russia
NCT06812728
Phase 2
Recruiting
100 patients
A phase II clinical trial compared standard TNT (mFolfox6 and CRT) with preoperative chemoradiotherapy (CRT) with neoadjuvant chemotherapy (CT) containing mFolfirinox in patients with locally advanced rectal cancer.
Egypt
NCT06475352
Phase 2
Recruiting
400 patients
The goal of this clinical trial is to establish guidelines for fluoropyrimidine dose reduction according to uracilemia in patients with DPD deficiency in the treatment of digestive cancers. The main question it aims to answer is:
\- Which reduction ...
France
NCT06791512
Phase 3
Recruiting
166 patients
Neoadjuvant immunotherapy has shown promising therapeutic effects in mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC). However, for patients with mismatch repair-proficient or microsatellite stable (pM...
China
NCT06269978
Phase 1
Recruiting
24 patients
Medications:
5-Fluorouracil
Oxaliplatin
This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class o...
United States
NCT06621563
Phase 1
Recruiting
780 patients
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid t...
China
NCT06750094
Phase 3
Recruiting
700 patients
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil,...
United States, Australia, Belgium, Brazil, China, France, Germany, Hong Kong, Hungary, India, Israel
NCT04516681
Phase 3
Recruiting
400 patients
Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the efficacy of AA. To date, no previous studies have investigated the c...
China
NCT06857773
Phase 3
Recruiting
306 patients
The goal of this randomized clinical trial is to investigate induction treatment with Hepatic Arterial Infusion Pump therapy combined with systemic therapy (HAIP-SYST) in chemotherapy-naive patients with unresectable colorectal liver metastases witho...
Netherlands
NCT06733038
Phase 3
Recruiting
238 patients
The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (...
Italy
NCT06540326
Phase 2
Recruiting
100 patients
Guidelines recommend FOLFIRI in combination with bevacizumab or cetuximab as a treatment option for advanced second-line colorectal cancer, and this study explores the efficacy and safety of a clinical study of liposomal irinotecan (II), fluorouracil...
China
NCT06643793
Phase 2
Recruiting
30 patients
To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.
China
NCT07562711
Phase 2
Recruiting
340 patients
This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery. It aims to investigate the impact of different adjuvant chemotherapy regimens on c...
China
NCT06625775
Phase 1
Recruiting
392 patients
Medications:
5-Fluorouracil
BBO-10203
Bevacizumab
Fulvestrant
Leucovorin
Oxaliplatin
Ribociclib
Trastuzumab
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
United States, Australia, Brazil, France, Spain
NCT06490536
Phase 3
Recruiting
700 patients
Medications:
5-Fluorouracil
Capecitabine
Ipilimumab
Irinotecan
Leucovorin
Nivolumab
Oxaliplatin
Panitumumab
Pertuzumab
Temozolomide
Trastuzumab
Background \& Rationale:
Colon cancer is a leading cause of cancer deaths, with a high recurrence rate in stage II high-risk and stage III patients due to undetectable micro-metastases. Liquid biopsy (LB) detects residual cancer DNA post-surgery and...
Germany, Italy, Spain
NCT06662786
Phase 3
Recruiting
1,000 patients
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLF...
United States, Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan
NCT06663319
Phase 1
Recruiting
260 patients
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic ...
United States, South Korea, Spain
NCT06598007
Phase 1
Recruiting
78 patients
This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patient...
United States
NCT06586515
Phase 1
Recruiting
630 patients
Medications:
5-Fluorouracil
Cetuximab
Gemcitabine
Irinotecan
LY3962673
Leucovorin
Nab-Paclitaxel
Oxaliplatin
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is exp...
United States, Canada, China, France, Germany, Ireland, Italy, Japan, Spain
NCT06831981
Not Applicable
Recruiting
264 patients
The goal of this clinical trial is to evaluate the efficacy of deep regional hyperthermia in the context of radiochemotherapy followed by consolidation chemotherapy in locally advanced rectal cancer.
Questions it aims to answer are:
* Can surgery b...
Germany
NCT06493760
Phase 2
Recruiting
130 patients
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination w...
China
NCT06603376
Phase 2
Recruiting
75 patients
Based on the upstream signaling features of BRAFV600E and the bypass feedback mechanisms, considering the pro-apoptotic effects of chemotherapy and the synergistic effects of targeted therapy, previous IMPROVEMENT trial creatively explored a balanced...
China
NCT06575127
Phase 2
Recruiting
60 patients
This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC). FOLFOXIRI, though effective, is known for its high toxicity, necessitating close monitor...
Egypt
NCT06279351
Phase 2
Recruiting
96 patients
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequ...
China
NCT06252649
Phase 3
Recruiting
450 patients
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb...
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Cz
NCT06205485
Phase 3
Recruiting
250 patients
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery?...
United States, Canada
NCT06428409
Phase 1
Recruiting
220 patients
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unr...
United States, Australia, Canada, Chile, China, Italy, Japan, South Korea, Spain, Switzerland, Taiwa
NCT06509126
Phase 3
Recruiting
500 patients
The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective in first line as the same regimen given continuously, resulting in a Time to Treatment Failure (TTF) not inferior to that obtained with standard continuo...
Italy
NCT06293625
Phase 3
Recruiting
150 patients
Colon cancer (CC) is the 5th most common cancer worldwide. Standard care for locally advanced disease is surgical resection followed by 3-6 months of adjuvant chemotherapy (AC) with oxaliplatin and 5-fluorouracil (OxFp).
Almost all of these patients...
France
NCT06640166
Phase 2
Recruiting
25 patients
The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.
Italy
NCT06324357
Phase 1
Recruiting
768 patients
Medications:
5-Fluorouracil
Capecitabine
Leucovorin
Oxaliplatin
Trastuzumab
Trastuzumab deruxtecan
Zanidatamab
Zongertinib
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not succe...
United States, Belgium, China, France, Germany, Italy, Japan, South Korea, Spain, United Kingdom
NCT06856447
Phase 1
Recruiting
22 patients
This study aims to evaluate the possible beneficial role of coenzyme Q10 against oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
Egypt
NCT06445062
Phase 1
Recruiting
1,130 patients
Medications:
5-Fluorouracil
Bevacizumab
Cetuximab
Gemcitabine
Irinotecan
Leucovorin
Nab-Paclitaxel
Oxaliplatin
RMC-6236
RMC-9805
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
The current subprotocols ...
United States
NCT06441565
Phase 2
Recruiting
84 patients
The objective of this clinical trial is to evaluate the efficacy and safety of combining fruquintinib with hepatic artery infusion (HAI)-FOLFOX in the treatment of refractory colorectal cancer with liver metastasis.
China
NCT06447727
Not Applicable
Recruiting
30 patients
To observe the PFS of yttrium \[90Y\] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.
China
NCT06242418
Phase 2
Recruiting
60 patients
Colon cancer is one of the most common malignant tumors with an increasing incidence rate in China. Surgical resection is still the main treatment for colon cancer at present. Radical surgery followed by three/six months chemotherapy is the standard ...
China
NCT06590259
Phase 2
Recruiting
20 patients
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its applicatio...
China
NCT06280495
Phase 2
Recruiting
156 patients
The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in the liver, increase T ...
China
NCT06179160
Phase 1
Recruiting
710 patients
Medications:
5-Fluorouracil
Cetuximab
Gemnabp
INCA33890
INCB161734
Irinotecan
Leucovorin
Oxaliplatin
Retifanlimab
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
United States, Australia, Belgium, Canada, France, Italy, Japan, Spain
NCT07253896
Phase 2
Recruiting
40 patients
Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer
China
NCT06218810
Phase 2
Recruiting
53 patients
The dual immunotherapy regimen significantly outperformed previous chemotherapy or immunomonotherapy for MSS type advanced CRC in two key efficacy indicators, ORR and PFS. Researchers have also conducted in-depth analysis of patient transcriptomics, ...
China
NCT05912075
Phase 1
Recruiting
78 patients
Compare two arms:
* Chemotherapy followed by tolinapant (ASTX660) in combination with Long-Course Radio Chemotherapy (LCRT), and
* Tolinapant (ASTX660) in combination with Short-Course Radiotherapy (SCRT) followed by chemotherapy For each patient, t...
France
NCT06131840
Phase 1
Recruiting
914 patients
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally ad...
United States, Canada, China, France, Netherlands, Spain, Sweden, United Kingdom
NCT06162650
Phase 2
Recruiting
42 patients
In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated. Patients with stage II or III middle/low rectal cancer will be prospective enrolled. The total neoadjuvant therapy with th...
Taiwan
NCT05959356
Phase 2
Recruiting
198 patients
The primary aim of phase II CEIL study is to evaluate the efficacy of cetuximab and envafolimab plus mFOLFOXIRI versus cetuximab plus mFOLFOX6 as first line treatment of patients with initially unresectable and previously untreated RAS/BRAF wild-type...
China
NCT06047379
Phase 1
Recruiting
134 patients
Medications:
5-Fluorouracil
Bevacizumab
Carboplatin
Ipilimumab
Irinotecan
Leucovorin
Nivolumab
Paclitaxel
Pembrolizumab
Regorafenib
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytom...
United States
NCT06154538
Phase 2
Recruiting
170 patients
The goal of this clinical trial is to compare the efficacy and safety of the combination of immune checkpoint inhibitors (ICIs) and FOLFOX regimen compared to FOLFOX regimen alone in the neoadjuvant chemotherapy of locally advanced colorectal cancer....
China
NCT05863195
Phase 3
Recruiting
408 patients
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver ...
United States
NCT06991465
Phase 2
Recruiting
35 patients
The combination of preoperative pelvic RT - either long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT)- followed by surgery has been the standard of care in the curative treatment of locally advanced adenocarcinoma of the rectum...
Canada
NCT05855200
Phase 3
Recruiting
892 patients
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high ...
United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, Estonia, Finland, Fran
NCT05954078
Phase 3
Recruiting
340 patients
Colorectal cancer (CRC) is one of the most common gastrointestinal tumors. According to the latest cancer report, the incidence and mortality rates of CRC are both ranked top 5 among malignant tumors worldwide and continue to rise. Patients who recei...
China
NCT05571644
Phase 2
Recruiting
143 patients
Neoadjuvant chemoradiotherapy (CRT) followed by total mesenteric excision (TME) and adjuvant chemotherapy was the standard of treatment for locally advanced rectal cancer (LARC) in the past two decades. The main obstacles for improving survival benef...
China
NCT05848739
Phase 1
Recruiting
130 patients
This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnorm...
United States
NCT05919264
Phase 1
Recruiting
595 patients
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
United States, Australia
NCT05462613
Phase 2
Recruiting
446 patients
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
France
NCT05786924
Phase 1
Recruiting
554 patients
Medications:
5-Fluorouracil
Cetuximab
Gemcitabine
Irinotecan
Leucovorin
Nab-Paclitaxel
Oxaliplatin
Panitumumab
S241656
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in particip...
United States, Denmark, Hong Kong, Japan, United Kingdom
NCT05564377
Phase 2
Recruiting
2,900 patients
Medications:
5-Fluorouracil
Alpelisib
Binimetinib
Fulvestrant
Ipatasertib
Leucovorin
Olaparib
Oxaliplatin
Paclitaxel
Palbociclib
Panitumumab
Sotorasib
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or ha...
United States, Puerto Rico
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
NCT05797467
Phase 3
Recruiting
366 patients
The goal of this clinical trial\] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with improved disease-fr...
China
NCT05462496
Phase 2
Recruiting
25 patients
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
United States
NCT05733000
Phase 2
Recruiting
94 patients
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lym...
United States
NCT05742425
Phase 2
Recruiting
30 patients
Multicentric randomised trial. The goal of this clinical research study is to evaluate the efficacy and safety of serplulimab combined with FOLFIRI+bevacizumab in the treatment of pMMR/Ras/BRAF wild-type unresectable peritoneal metastasis of colon ca...
China
NCT05797077
Phase 3
Recruiting
346 patients
The goal of this clinical trial is to compare in resectable liver metastases colorectal cancer patients.The main question it aims to answer is to investigate whether the progression-free survival (PFS) of resectable colorectal liver metastasis (CRLM)...
China
NCT05815082
Phase 3
Recruiting
490 patients
The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is non-inferior to adjuva...
China
NCT05534087
Phase 3
Recruiting
236 patients
This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to stan...
South Korea
NCT06826092
Phase 2
Recruiting
110 patients
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
Taiwan
NCT05458219
Phase 1
Recruiting
470 patients
This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors. It is planned to be carried out in di...
United States, Australia, China
NCT05253651
Phase 3
Recruiting
400 patients
Medications:
5-Fluorouracil
Bevacizumab
Cetuximab
Leucovorin
Levoleucovorin
Oxaliplatin
Trastuzumab
Tucatinib
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take th...
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, France, Germany
NCT05286814
Phase 2
Recruiting
70 patients
Background:
One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight can...
United States
NCT05412082
Phase 1
Recruiting
25 patients
The purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (LARC) with chemotherapy first and then follow with radiation therapy to a higher dose than what is usually delivered an...
United States
NCT05489211
Phase 2
Recruiting
454 patients
Medications:
5-Fluorouracil
Bevacizumab
Capecitabine
Carboplatin
Cisplatin
Rilvegostomig
Volrustomig
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
United States, Canada, China, France, Germany, Italy, Japan, Poland, South Korea, Spain, Switzerland
NCT05464030
Phase 1
Recruiting
200 patients
The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2)...
United States, Canada, Japan, South Korea, Spain
NCT05379595
Phase 1
Recruiting
225 patients
The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) and to chara...
United States, Belgium, Canada, China, Germany, Italy, Malaysia, Puerto Rico, South Korea, Spain, Ta
NCT05727163
Phase 2
Recruiting
194 patients
This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus systemic intravenous...
China
NCT05174169
Phase 2
Recruiting
1,912 patients
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
United States, Canada, Puerto Rico
NCT05355701
Phase 1
Recruiting
267 patients
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors.
This study is seeking pa...
United States, Canada, Israel
NCT05382559
Phase 1
Recruiting
681 patients
Medications:
5-Fluorouracil
Carboplatin
Cetuximab
Cisplatin
Docetaxel
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Pembrolizumab
Pemetrexed
Setidegrasib
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific m...
United States, China, France, Japan, Puerto Rico, South Korea, Spain
NCT06002789
Phase 2
Recruiting
17 patients
At present, radical resection ± preoperative neoadjuvant chemotherapy for colorectal cancer is still the standard comprehensive treatment. In recent years, immunotherapy of PD-1 monoclonal antibody has a significant effect in the second-line/first-l...
China
NCT05024097
Phase 2
Recruiting
43 patients
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemoth...
United States
NCT05067283
Phase 1
Recruiting
830 patients
Medications:
5-Fluorouracil
Calderasib
Carboplatin
Cetuximab
Leucovorin
Oxaliplatin
Pembrolizumab
Pemetrexed
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRA...
United States, Argentina, Australia, Canada, Chile, China, Denmark, Israel, Italy, Japan, Lithuania,
NCT05008809
Phase 3
Recruiting
507 patients
This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with metastatic colorectal cancer after definite interventional therapy of all lesions are randomized in a 2:1 fashion (favoring active thera...
Germany
NCT04749108
Phase 2
Recruiting
1,075 patients
Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity. Surgery alone can cure only one out of two patients, radiochemotherapy improves the local control but the metastatic ...
France
NCT04991948
Phase 1
Recruiting
34 patients
The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.
United States, Belgium
NCT04929223
Phase 1
Recruiting
542 patients
Medications:
5-Fluorouracil
Atezolizumab
Bevacizumab
Cetuximab
Divarasib
Inavolisib
Irinotecan
Leucovorin
Oxaliplatin
SY-5609
Tiragolumab
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive a...
United States, Australia, Canada, Denmark, Germany, Italy, Poland, South Korea, Spain, Taiwan, Unite
NCT04847063
Phase 1
Recruiting
60 patients
Background:
Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS with HIPEC may help people with peritoneal carcinomatosis. These are tumors that have sprea...
United States
NCT05424692
Not Applicable
Recruiting
200 patients
Medications:
5-Fluorouracil
Leucovorin
The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and exp...
China
NCT05201430
Phase 3
Recruiting
300 patients
This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimiz...
China
NCT05022030
Phase 2
Recruiting
150 patients
This prospective, randomized, phase 2 study is conducted to evaluate the efficacy and safety of first line mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS and BRAF genes.
China
NCT05179889
Phase 2
Recruiting
308 patients
A multicenter, open labeled randomized, phase II trial comparing mFOLFIRINOX and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer
South Korea
NCT04808323
Phase 1
Recruiting
22 patients
This study is a prospective, open-label, phase I design.
United States
NCT04999761
Phase 1
Recruiting
917 patients
Medications:
5-Fluorouracil
AB122
AB154
Bevacizumab
Carboplatin
Cisplatin
Gemcitabine
Nab-Paclitaxel
Ramucirumab
TAS-115
TAS-116
TAS-120
Trifluridine
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
Japan
NCT04861558
Phase 3
Recruiting
213 patients
A dose titration study and a combined superiority registry-based open-label randomized control trial is planned to answer the trial objectives. The study will be registry-based to allow simpler and more comprehensive follow-up. Patients with colorect...
India, Sweden
NCT04703101
Phase 1
Recruiting
25 patients
This phase I trial investigates how well short-course radiation therapy followed by combination chemotherapy works in treating patients with stage II-III rectal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. ...
United States
NCT04687631
Phase 3
Recruiting
508 patients
Evidence suggests that the addition of cetuximab or bevacizumab to doublet regimens could improve response rate and resectability rate of liver metastases and survival in colorectal liver metastases (CRLM). Moreover, it is observed that FOLFOXIRI yie...
China
NCT04689347
Phase 1
Recruiting
27 patients
An upfront-intensified treatment combining all the three active cytotoxic agents in metastatic colorectal cancer (mCRC) including fluoropyrimidines, oxaliplatin, irinotecan (FOLFOXIRI) plus antiangiogenic blockade with bevacizumab significantly impro...
Italy
NCT04495088
Phase 3
Recruiting
550 patients
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure
Germany
NCT04421820
Phase 1
Recruiting
220 patients
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. ...
United States, Canada, Germany, Ireland, Italy, South Korea, Spain
NCT04329494
Phase 1
Recruiting
49 patients
This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the lining of the abdominal ca...
United States
NCT04485013
Phase 1
Recruiting
240 patients
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 in...
United States
NCT03803553
Phase 3
Recruiting
400 patients
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer.
The names of the potential treatments involved in this study are:
* Active surveillance
* FOLFIRI...
United States
NCT04215731
Phase 3
Recruiting
582 patients
Multimodality treatment that comprises preoperative fluoropyrimidine with concurrent radiotherapy followed by total mesorectal excision (TME) surgery and adjuvant fluoropyrimidine-based chemotherapy is recommended as a standard treatment of patients ...
China
NCT04120701
Phase 3
Recruiting
1,980 patients
The objective of CIRCULATE trial is to improve care of patients after colon tumor surgery, based on an innovative marker: circulating tumor DNA.
France
NCT03516708
Phase 1
Recruiting
49 patients
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
United States
NCT03874026
Phase 2
Recruiting
34 patients
Patients' selection thorough the identification of predictive factors still represent a challenge in metastatic colorectal cancer (mCRC). Cetuximab (Erbitux®), a chimeric monoclonal antibody binding to the Epidermal Growth Factor Receptor (EGFR), be...
Italy
NCT03925662
Phase 3
Recruiting
40 patients
mebendazole treating colon cancer
Egypt
NCT03692429
Phase 1
Recruiting
49 patients
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
United States, Belgium
NCT03671252
Phase 3
Recruiting
776 patients
Preoperative radiation and chemotherapy is the standard treatment for local advanced rectal cancer. The addition of oxaliplatin to capecitabine combined with radiotherapy does not improve local control and long-term survival. Most importantly,chemora...
China
NCT03715933
Phase 1
Recruiting
411 patients
Medications:
5-Fluorouracil
Bevacizumab
Carboplatin
INBRX-109
Irinotecan
Leucovorin
Pemetrexed
Temozolomide
Tipiracil
Trifluridine
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
United States, France, Italy, Netherlands, Spain, United Kingdom
NCT05378919
Phase 2
Recruiting
250 patients
Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging
Lithuania
NCT02355379
Phase 3
Recruiting
774 patients
Colorectal cancer occurs mainly in elderly patients. Recent estimation showed that in France more than 50% of the patients diagnosed with a colorectal cancer are 70 years old or more. Adjuvant chemotherapy has demonstrated a benefit on disease-free s...
France
NCT06818812
Phase 1
Active
30 patients
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
United States
NCT06268015
Phase 2
Active
16 patients
This is a single-arm, interventional, pilot clinical trial. Fifteen evaluable patients will have tumor-informed ctDNA testing at baseline and start botensilimab and balstilimab treatment. They will receive botensilimab and balstilimab in 6-week cycle...
United States
NCT06688786
Not Applicable
Active
30 patients
Preoperative neoadjuvant chemoradiotherapy can induce tumor regression and reduce the risk of postoperative recurrence, serving as the standard treatment for locally advanced rectal cancer. However, neoadjuvant radiotherapy may increase the risk of p...
China
NCT06607185
Phase 1
Active
750 patients
Medications:
5-Fluorouracil
Carboplatin
Cetuximab
Cisplatin
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Pembrolizumab
Pemetrexed
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in co...
United States, Belgium, France, Germany, Italy, Japan, Spain, Taiwan
NCT06544655
Phase 1
Active
213 patients
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stab...
United States, Australia, Canada
NCT06509880
Phase 1
Active
200 patients
The goal of this study type: clinical trial is to primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc. and improve the quality of life and reduce one-year mortality in palliative treatment of metastatic fo...
Kazakhstan
NCT06328738
Phase 1
Active
275 patients
Medications:
5-Fluorouracil
Capecitabine
ELVN-002
Eribulin
Leucovorin
Oxaliplatin
Paclitaxel
Trastuzumab
The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in par...
United States, Belgium, France, Italy, Netherlands, South Korea, Spain
NCT06106308
Phase 2
Active
110 patients
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bev...
United States
NCT06011772
Early Phase 1
Active
2 patients
The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in...
United States
NCT06107413
Phase 2
Active
280 patients
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid...
United States, Belgium, Germany, Israel, Japan, South Korea, Spain, Taiwan
NCT05945901
Phase 2
Active
669 patients
This is a double-blind, randomized, multi-center, II/III study in at least 606 patients with advanced colorectal cancer. The study is being conducted to evaluate the safety of HR070803 combined with oxaliplatin, 5-FU/LV and bevacizumab in phase II an...
China
NCT05843188
Phase 2
Active
155 patients
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).
Up to 155 patients will be screened for DTP-signatur...
Canada
NCT05969899
Phase 2
Active
50 patients
The goal of this prospective clinical trial is to evaluate efficacy and safety of irinotecan liposomes for first-line treatment of advanced colorectal cancer. The primary endpoint is Objective response rate (ORR) per RECIST 1.1. The secondary endpoin...
China
NCT05846867
Phase 1
Active
170 patients
This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC
China
NCT05627635
Phase 1
Active
20 patients
This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal cancer that has spre...
United States
NCT05609370
Phase 1
Active
113 patients
This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and LBL-007 in combination with bevacizumab plus fluoropyrimidine versus bevacizum...
United States, Australia, China, Puerto Rico
NCT05647122
Phase 1
Active
167 patients
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics ...
United States, Australia, Canada, China, France, Italy, Japan, Malaysia, South Korea, Spain, Taiwan
NCT06417476
Phase 2
Active
66 patients
Given the growing focus on preserving organ function and the utilization of neoadjuvant therapy, it is important to investigate and enhance the application of comprehensive neoadjuvant therapy in low rectal cancer. This approach aims to minimize or c...
China
NCT05610163
Phase 2
Active
783 patients
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxali...
United States, Puerto Rico
NCT05585320
Phase 1
Active
209 patients
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved a...
United States
NCT04929028
Phase 2
Active
40 patients
This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating ...
United States
NCT05382442
Phase 2
Active
254 patients
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.
United States, China
NCT05239741
Phase 3
Active
100 patients
In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothes...
China
NCT05009069
Phase 2
Active
58 patients
This study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with locally advanced rectal cancer (LARC). The study consists of a safety run-in p...
China
NCT05253846
Phase 2
Active
63 patients
The aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
Italy
NCT05108428
Early Phase 1
Active
20 patients
The purpose of the study is to determine the feasibility of using magnetic resonance imaging (MRI)-guided adaptive chemoradiation therapy to improve response to treatment.
United States
NCT05121038
Phase 1
Active
50 patients
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
United States
NCT06540261
Phase 1
Active
65 patients
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorecta...
Japan
NCT05030493
Not Applicable
Active
787 patients
The main aim of the study is to check gene change in tumor tissues with an additional analysis of the data from PARADIGM Exploratory Study, which is conducted for people with advanced/recurrent colorectal cancer.
In the PARADIGM Exploratory Study (N...
Japan
NCT04898504
Phase 2
Active
45 patients
Patients with colorectal livermetasteses and heavy tumour burden and progression on 1st line chemotherapy have no other available treatment in Norway today other than 2nd line chemotherapy. The Investigators will randomize patients to HAI-floxuridine...
Norway
NCT04793958
Phase 3
Active
461 patients
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, Den
NCT05312398
Phase 2
Active
219 patients
This clinical program aims to evaluate the activity and efficacy of cetuximab continuation of treatment for three lines of therapy with rotation of chemotherapy (FOLFIRI, FOLFOX, irinotecan) in mCRC patients, whose tumors remain RAS/BRAF WT. The stud...
Italy
NCT04595266
Phase 2
Active
48 patients
Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial.
The patients will be randomized in a 1: 1 ratio in two arms:
Control arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimen...
Spain
NCT04864067
Phase 2
Active
73 patients
This study is designed to explore the hypothesis that in patients with a Locally advanced rectal cancer (LARC) treated with a Total neoadjuvant therapy (TNT) strategy based on short course radiotherapy (5x5Gy) followed by neoadjuvant consolidation ch...
Chile
NCT06547385
Phase 1
Active
40 patients
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in ...
Japan
NCT03426904
Phase 3
Active
708 patients
The main cause of recurrence after surgical treatment of colon cancer is distant metastasis. Neoadjuvant chemotherapy has potential benefits of improving the effectiveness of chemotherapy. Preoperative chemotherapy may eradicate microscopic metastati...
South Korea
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
NCT05673772
Phase 2
Active
364 patients
The treatment protocol proposed in this study is to perform short-term radiation therapy and 4 cycles of FOLFOX chemotherapy for neoadjuvant treatment of locally advanced rectal cancer. Compared to conventional chemoradiation therapy, the preoperativ...
South Korea
NCT04587128
Phase 2
Active
34 patients
The study will use previously established doses of panitumumab or cetuximab in the metastatic setting for the treatment of unresectable colorectal cancer (CRC). It is designed to investigate an alternative treatment strategy to maximize the benefit t...
United States
NCT04430738
Phase 2
Active
40 patients
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effec...
United States, Japan
NCT04230187
Phase 3
Active
528 patients
The current clinical trials and data on the triplet regimen combined with bevacizumab for first-line treatment of metastatic colorectal cancer were from European and American populations. The triplet regimens recommended by the NCCN and ESMO guidelin...
China
NCT04245865
Phase 2
Active
83 patients
This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other hal...
Denmark
NCT03203525
Phase 1
Active
38 patients
This phase I trial studies the side effects and best dose of combination chemotherapy and bevacizumab, and to see how well they work with the NovoTTF-100L(P) system in treating participants with cancer that has come back or does not respond to treatm...
United States
NCT04166318
Phase 2
Active
252 patients
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin,...
United States
NCT04068103
Phase 2
Active
635 patients
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tum...
United States, Canada, Puerto Rico
NCT04094688
Phase 3
Active
455 patients
This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body. Vitamin D3 helps the body use calcium and phosphorus to ma...
United States, Puerto Rico
NCT04068610
Phase 1
Active
61 patients
COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-C...
United States, Australia, Canada, France, Spain
NCT04008030
Phase 3
Active
839 patients
Medications:
5-Fluorouracil
Bevacizumab
Cetuximab
Ipilimumab
Irinotecan
Leucovorin
Nivolumab
Oxaliplatin
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monother...
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmar
NCT03879109
Phase 3
Active
58 patients
GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous pelvic radiotherapy for the primary rectal cancer. This situation leads to a 20% higher risk of non-curative resection for the LRRC management (R1 status) impa...
France
NCT03781323
Phase 2
Active
12 patients
The purpose of this study is to evaluate the treatment of patients with locally advanced rectal cancer for complete response to neoadjuvant chemotherapy without the use of radiation and surgery.
United States
NCT03921684
Phase 2
Active
29 patients
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients. Subjects must have received no prior treatme...
Israel
NCT03795311
Phase 1
Active
32 patients
In patients in progression after oxaliplatin and irinotecan, the study FOLFIRINOX 3 proposes to evaluate the interest of modifying the standard pattern of administration of the molecule of irinotecan in order to make it more efficient. In combination...
France
NCT03337087
Phase 1
Active
18 patients
Medications:
5-Fluorouracil
Rucaparib
This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic, colorectal, gastroesop...
United States
NCT03635021
Phase 3
Active
419 patients
The purpose of this study is to assess the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic,...
Spain
NCT03548961
Phase 2
Active
19 patients
This is a single arm phase II study of neoadjuvant chemotherapy followed by local excision and post-operative chemoradiotherapy in patients with early stage, low rectal adenocarcinoma. After completion of pre-treatment tests/procedures (including pel...
United States
NCT03493048
Phase 2
Active
146 patients
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype. The patients will be treated in two therapy gr...
China
NCT02997228
Phase 3
Active
120 patients
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (prima...
United States
NCT03391843
Phase 2
Active
100 patients
A number of pilot studies had shown high rate of complete resection after neoadjuvant chemotherapy alone for local advanced rectal cancer(LARC), but they did not increase the ratio of pathological complete response (pCR) which was associated with imp...
China
NCT02912559
Phase 3
Active
712 patients
This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (d...
United States, Germany, Puerto Rico
NCT02980510
Phase 2
Active
219 patients
National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.
Evaluation of complete respon...
France
NCT02688712
Phase 2
Active
50 patients
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer. Also as part of this study, research will be done on tumor samples to see if it is possi...
United States
NCT02671435
Phase 1
Active
383 patients
This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination...
United States, Australia, Belgium, Canada, France, Hungary, Italy, New Zealand, South Korea, Spain,
NCT02572141
Phase 3
Active
738 patients
BACKGROUND:
In patients with high risk stage II and stage III colon cancer (CC), curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become a standard treatment. However, 20 to 30 % of these patients will develop dis...
China
NCT02008656
Phase 2
Active
358 patients
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have an improved 3-year dis...
United States
NCT01941641
Phase 2
Active
40 patients
Objective tumour response rate to FOLFOXIRI to pre-operative therapy.
Hong Kong
NCT01792934
Not Applicable
Active
478 patients
The purpose of this study is to compare overall survival rates of colorectal cancer patients with multi-organ metastases with an indication for first line systemic treatment randomized for treatment with combination chemotherapy or treatment with com...
Netherlands, United Kingdom
NCT01460589
Phase 3
Active
303 patients
This study sets up the final study end point and three detailed goals as the following.
The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after surgery compared with co...
South Korea
NCT00335816
Phase 2
Active
248 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopp...
United States, Canada
NCT00492999
Phase 2
Active
64 patients
RATIONALE: Hepatic arterial infusion uses a catheter to carry tumor-killing substances directly into the liver. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from ...
United States
NCT00217737
Phase 3
Active
2,431 patients
This randomized phase III trial studies oxaliplatin, leucovorin, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. ...
United States, Canada, Peru, Puerto Rico, South Africa
NCT06890624
Phase 2
Not yet recruiting
138 patients
In patients with high-risk stage II and stage III colon cancer, curative surgery followed by adjuvant chemotherapy with FOLFOX or CAPOX regimens has become the standard treatment. However, 20 to 30% of these patients will develop distant metastasis, ...
NCT07359456
Phase 2
Not yet recruiting
130 patients
The goal of this clinical trial is to evaluate the superiority of ivonescimab combined with FOLFIRI over FOLFIRI + bevacizumab as second-line treatment of non resectable pMMR/MSS BRAFwt mCRC patients without liver metastases in terms of PFS. The main...
France
NCT07662031
Phase 2
Not yet recruiting
25 patients
This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).
United States
NCT07363408
Phase 1
Not yet recruiting
30 patients
This phase I trial studies the safety, side effects, and best dose of ADG126, in combination with ivonescimab alone, in combination with ivonescimab, leucovorin, and fluorouracil, or in combination with ivonescimab and leucovorin, fluorouracil, and i...
United States
NCT07271355
Phase 3
Not yet recruiting
129 patients
This phase III trial studies how well pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with mitomycin works versus (vs) standard chemotherapy (leucovorin calcium, fluorouracil, and irinotecan hydrochloride \[FOLFIRI regimen\] plus bevaciz...
United States
NCT07622017
Phase 2
Not yet recruiting
24 patients
This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.
KRC-01 is an investigational product designe...
France
NCT07649655
Phase 1
Not yet recruiting
120 patients
This is an open-label, multicenter, Phase Ib trial designed to evaluate the safety, tolerability, and preliminary efficacy of EMB-01 in combination with chemotherapy in patients with unresectable or metastatic colorectal cancer (CRC), and to determin...
NCT07543471
Phase 1
Not yet recruiting
387 patients
This is a multicentre, randomized, double-blind, parallel-controlled Phase 1 clinical study designed to evaluate the pharmacokinetic (PK) similarity, efficacy, safety, and immunogenicity of HLX05-N compared with US-sourced ERBITUX® and EU-sourced ER...
NCT07318389
Early Phase 1
Not yet recruiting
100 patients
Medications:
5-Fluorouracil
Adagrasib
Bevacizumab
Cetuximab
Encorafenib
Irinotecan
Leucovorin
Oxaliplatin
Panitumumab
Sotorasib
Trastuzumab deruxtecan
Tucatinib
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
United States
NCT07621497
Phase 2
Not yet recruiting
229 patients
This is a prospective, multicenter, randomized controlled, phase II study. It is expected to enroll 229 patients and aims to evaluate the efficacy and safety of FOLFOX8 versus mFOLFOX6 combined with bevacizumab or cetuximab as first-line treatment fo...
China
NCT07659795
Phase 2
Not yet recruiting
150 patients
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
NCT07585279
Phase 2
Not yet recruiting
408 patients
Phase II - Treatment Regimen Exploration Stage:
1. Evaluate the safety and efficacy of the following three treatment regimens:
Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart (Group A) Liposomal irinotecan + 5-FU/LV + bevacizumab (Gr...
China
NCT07340567
Phase 3
Not yet recruiting
2,450 patients
CIRCULATE-III is an international, multicenter, open-label, randomized phase III trial designed to use ctDNA as a selection criterion for intensification or de-escalation of adjuvant chemotherapy. Eligible patients are randomly assigned to the follow...
France, Sweden
NCT07549399
Phase 3
Not yet recruiting
204 patients
To explore the efficacy and safety of an intensified treatment regimen consisting of short-course radiotherapy followed by mFOLFOX6 chemotherapy combined with precise targeted therapy (based on RAS/BRAF status: cetuximab for wild-type, bevacizumab fo...
China
NCT07391566
Phase 1
Not yet recruiting
99 patients
This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients w...
China
NCT07472868
Phase 3
Not yet recruiting
394 patients
The aim of this clinical trial is to compare triplet induction therapy (FOLFOXIRI) with doublet induction therapy (CAPOX/FOLFOX), followed by chemoradiotherapy and either surgery or a watch-and-wait approach, in patients with high-risk locally advanc...
Netherlands
NCT07446465
Phase 4
Not yet recruiting
42 patients
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
China
NCT07337551
Phase 2
Not yet recruiting
20 patients
This study is a single-center, single-arm clinical trial involving patients with TP53-mutated and LRPPRC-positive metastatic colorectal cancer. It aims to evaluate the efficacy and safety of gossypol acetate tablets combined with bevacizumab and the ...
NCT07381400
Phase 2
Not yet recruiting
128 patients
This multicenter, randomized controlled clinical trial (FIRM02 Study) aims to evaluate the effectiveness and safety of neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor (Serplulimab) in patients with MSS/pMMR locally advanced rectal canc...
NCT07229846
Phase 2
Not yet recruiting
30 patients
Medications:
5-Fluorouracil
Aipalolitovorelizumab
Bevacizumab
Capecitabine
Irinotecan
Leucovorin
Oxaliplatin
This is an open-label, single-arm, single-center phase II clinical study, aiming to investigate the safety and efficacy of Aipalolitovorelizumab (QL1706) combined with bevacizumab plus standard chemotherapy regimen as first-line treatment for patient...
China
NCT07004413
Phase 3
Not yet recruiting
267 patients
The goal of this clinical trial is to learn if the application of the chemotherapy FOLFIRI and cetuximab works better when given with scheduled breaks or continuously in adults with metastatic colorectal cancer. The main question it aims to answer is...
Germany
NCT07277842
Phase 3
Not yet recruiting
382 patients
The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with pMMR locally advance...
China
NCT07118800
Phase 3
Not yet recruiting
160 patients
The primary objective of the NACRE-2 trial is to assess whether the addition of chemotherapy after short-course radiotherapy is more effective than short-course radiotherapy alone in elderly patients with locally advanced rectal cancer. Secondary obj...
NCT07175636
Phase 2
Not yet recruiting
66 patients
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4, code name only) plus ...
NCT07123441
Phase 2
Not yet recruiting
300 patients
This is a single-arm, open-label clinical trial designed to evaluate the efficacy and safety of irinotecan liposome (II), 5-FU/LV in combination with bevacizumab for the treatment of advanced colorectal cancer.
China
NCT07021950
Phase 2
Not yet recruiting
130 patients
This study is a multicenter, open-label phase II trial conducted to assess the safety and antitumor activity of Ivonescimab (AK112) plus FOLFIRI versus bevacizumab plus FOLFIRI as second-line treatment in subjects with MSS/pMMR metastatic colorectal ...
NCT07070713
Phase 2
Not yet recruiting
44 patients
This is a two-arm, randomized phase II clinical study. It is planned to enroll 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer. After signing the informed consent, eligible subjects will be screened to enter t...
China
NCT07074353
Phase 3
Not yet recruiting
360 patients
This study enrolled patients with locally advanced rectal cancer. The experimental group received irinotecan liposomes combined with standard total neoadjuvant therapy (TNT), while the control group received standard TNT. The study endpoints were the...
China
NCT06972498
Phase 2
Not yet recruiting
35 patients
The population receiving ivosimab combined with chemotherapy for neoadjuvant treatment of colorectal cancer liver metastasis.
NCT06959693
Phase 2
Not yet recruiting
590 patients
This is a prospective randomized controlled Phase Ⅱ/Ⅲ Clinical study to evaluate the clinical efficacy and safety of Envafolimab combining with Cetuximab -β and mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC...
China
NCT06963502
Phase 1
Not yet recruiting
762 patients
Medications:
5-Fluorouracil
Adebrelimab
Capecitabine
HS-10370
HS-20093
HS-20117
Leucovorin
Oxaliplatin
Platinum
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid ...
China
NCT07000305
Phase 2
Not yet recruiting
42 patients
A study of Cetuximabβ combined with Envolimab and mFOLFOX6 in Subjects with Advanced Colorectal Cancer
China
NCT06855849
Phase 2
Not yet recruiting
85 patients
This trial is a multicenter, single arm study of efficacy of amivantamab in combination with FOLFIRI in RAS/BRAF wild-type advanced colorectal cancer patients progressed prior treatment including oxaliplatin based chemotherapy. This trial will be con...
South Korea
NCT06899477
Phase 3
Not yet recruiting
714 patients
This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with advanced colon cancer, including the upper third of the rectum, clinically staged cT3-4 and or cN+ (defined as lymph nodes with short ax...
Germany
NCT06652412
Phase 2
Not yet recruiting
124 patients
This is a prospective, multicentre, cohort study. For cohort 1, experimental cohort, older or Frail patients with inoperable localized colorectal cancer will receive Ultrafractionated Radiotherapy (RT) and Comprehensive Geriatric Assessment (CGA) Gui...
NCT06616259
Phase 3
Not yet recruiting
452 patients
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided mCRC.
China
NCT06491355
Phase 2
Not yet recruiting
72 patients
This is a prospective, multi-center, randomized controlled clinical intervention study, aiming to explore the effectiveness and safety of mfolfox6 and hlx04 regimens combined with slulimumab as first-line treatment for MSS-type initial unresectable m...
China
NCT06415851
Phase 2
Not yet recruiting
36 patients
Fluorouracil and oxaliplatin-based combined with molecular targeted drugs are still the main treatment strategies for patients with advanced metastatic colorectal cancer (mCRC). Multiple studies have confirmed that anti-PD-1 combined chemotherapy reg...
China
NCT06049758
Not Applicable
Not yet recruiting
80 patients
Evaluating the differences between D2 and D3 lymphadenectomy in laparoscopic right hemicolectomy in patients with right cancer colon post-operative outcome, intra-operative blood transfusion, post-operative ICU admission, anastomotic leakage, lymph n...
Egypt
NCT06099951
Phase 2
Not yet recruiting
53 patients
For locally advanced rectal cancer, the initial goal of neoadjuvant chemoradiotherapy is to reduce local recurrence, but the pathologic complete response (PCR) rate is low, and distant metastasis becomes the main treatment failure pattern. With the g...
NCT05948072
Phase 3
Not yet recruiting
250 patients
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach. However, there is ongoing debate regarding the optimal treatment strategy. Our stu...
China
NCT05427669
Phase 3
Not yet recruiting
340 patients
Surgery is the main treatment method for colon cancer. About 50% of patients can be cured with surgery alone. For colon cancer with high-risk stage II or III after surgery, the current guidelines recommend 3-6 months after surgery. adjuvant chemother...
NCT05239650
Phase 2
Not yet recruiting
50 patients
This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX...
NCT04838496
Phase 2
Not yet recruiting
128 patients
Despite developments in the multidisciplinary treatment of patients with locally advanced rectal cancer (LARC), such as the introduction of total mesorectal excision (TME) by Heald et al. and the shift from adjuvant to neoadjuvant (chemo)radiotherapy...
Netherlands
NCT04443543
Phase 2
Not yet recruiting
222 patients
The study is designed to test the hypothesis that the clinical complete response (CCR) rate of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy will increase after an adaptive-design paradigm, as well as ...
China
NCT03975049
Phase 3
Not yet recruiting
933 patients
Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of locally advanced rectal cancer.
Local irradiation significantly increases surgical complications and impairs quality of life.
Combination chemotherapy alone...
NCT07441369
Phase 2
Active
16 patients
This is a single-center, single-arm, open-label clinical study, to explore the efficacy and safety of abemaciclib combined with FOLFOX/FOLFIRI regimen in patients with advanced colorectal liver metastases cancer who failed standard two or three-line ...
China
NCT07323576
Phase 2
Active
164 patients
This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation. The study has a safety run-in ...
NCT06501989
Phase 2
Active
10 patients
The purpose of this research is to see if adjusting the dose of 5-fluorouracil based on its concentration in your blood will improve the treatment of your metastatic colon cancer.
United States
NCT05375708
Phase 2
Active
93 patients
Medications:
5-Fluorouracil
Leucovorin
A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation). However, it is unclear if patients with more extensive metastatic disease benefit from local th...
Netherlands
NCT07334587
Not Applicable
Completed
248 patients
This randomized controlled trial is designed to compare the efficacy and safety of two commonly used chemotherapy regimens, FOLFOX-6 and CAPOX, in adults with metastatic colorectal carcinoma who are receiving chemotherapy after surgery at the Departm...
Pakistan
NCT06936527
Phase 1
Active
102 patients
XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation
China
NCT06959589
Phase 2
Active
50 patients
This is an open-label, multicenter, single-arm Phase II clinical study, divided into subgroups A and B:
Cohort A - To evaluate the efficacy and safety of IBI351, cetuximab β combined with FOLFIRI as first-line treatment for metastatic colorectal ca...
China
NCT06509906
Phase 1
Completed
59 patients
The purpose of this study is to evaluate the safety and preliminary clinical activity of M9466 in combination with topoisomerase 1 inhibitors-based regimens. As such the combination with FOLFIRI (folinic acid, fluorouracil, irinotecan) and Bevacizuma...
United States, Australia, Japan, South Korea, Spain
NCT06363552
Phase 2
Completed
36 patients
The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.
China
NCT06335147
Not Applicable
Completed
23 patients
Evaluate the efficacy and safety of PD1 monoclonal antibody combined with mFOLFOX6 neoadjuvant therapy for advanced resectable metastatic colon cancer with enriched pro-inflammatory pan macrophage subpopulations
NCT06332079
Phase 2
Completed
46 patients
The aim of this study is to assess the efficacy of 166Ho-TARE followed by maintenance therapy with fluoropyrimidine and anti-EGFR or bevacizumab in liver-limited unresectable colorectal cancer patients, in terms of progression free rate 9- and 8-mont...
Italy
NCT06269445
Phase 4
Completed
20 patients
To evaluate the efficacy and safety of the combination regimen of Icaritin with bevacizumab + FOLFIRI in patients with liver metastases from advanced colorectal cancer.
China
NCT06010888
Phase 2
Completed
92 patients
The goal of this clinical trial is to learn about the efficacy and safety of Fruquintinib with mFOLFOX6/FOLFIRI in patients with mCRC. The main question it aims to answer is:
The conversion surgery rate of the therapy mentioned above. The ORR, R0 su...
China
NCT05983367
Phase 2
Completed
70 patients
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202-01) in patients with previously treated RAS mutant advanced or metastatic CRC. All patients will receive treatment with FOLFIRI and bevacizumab. In addition,...
Belgium, France, Spain
NCT05062889
Phase 2
Completed
477 patients
The aims of this study are to evaluate if an intensified adjuvant treatment with FOLFOXIRI could increase the rate of cases with undetectable ct-DNA after chemotherapy and to evaluate if a further adjuvant treatment with Trifluridine/Tipiracil could ...
Italy
NCT05640726
Phase 2
Completed
30 patients
To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases
NCT05678257
Phase 2
Completed
180 patients
This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with unresectable metast...
United States, France, Germany, Italy, Spain, United Kingdom
NCT05593328
Phase 2
Completed
23 patients
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil \[5-FU\], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed met...
United States
NCT05714553
Phase 1
Completed
19 patients
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with other agents for the ...
United Kingdom
NCT07024537
Phase 2
Completed
24 patients
This study was a phase 2, single-arm, single-center clinical trial in which previously treated patients with unresectable colorectal cancer liver metastases.
China
NCT05352165
Not Applicable
Completed
192 patients
This is a prospective multicenter randomized controlled trial study. According to the enrollment criteria, patients with locally advanced rectal cancer who need neoadjuvant therapy before radical surgery were randomly divided into the organoids drug ...
NCT05634590
Phase 2
Completed
68 patients
RAS mutations are found in nearly half of colorectal cancer patients. However, there is no targeted driver gene drugs have been approved for RAS-mutated patients. For RAS mutant metastatic colorectal cancer, the commonly used treatment regimen is bev...
China
NCT05111860
Phase 1
Completed
20 patients
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer
China
NCT06048146
Not Applicable
Completed
180 patients
The goal of this clinical trial is to compare in newly diagnosed patients with resectable rectal cancer with lateral lymph node metastasis. This study aims to
* further verify the safety and efficacy of FOLFOXIRI three-drug regimen
* Using multiple ...
China
NCT05480306
Phase 2
Completed
188 patients
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) \[FOLFIRI/FOLFOX and bevacizumab\] as second-line t...
United States, Germany, South Korea
NCT05522738
Phase 1
Completed
46 patients
Molecular subtypes make difference on clinicopathologic features and response to chemotherapy and targeted agents as well as prognosis. RAS mutation status, which accounting for approximately 35% to 40% of colorectal cancer patients, is an important ...
China
NCT05330429
Phase 2
Completed
77 patients
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advance...
United States, Australia, Belgium, Canada, France, Germany, Hong Kong, Italy, Puerto Rico, Spain
NCT05358704
Phase 2
Active
38 patients
To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI and to Escalate Complete Response for Rectal Cancer patients.Go through laboratory and medical tests to verify eligibility to enter the study, receive the ex...
United States
NCT05362825
Not Available
Completed
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including the response rate, the...
Vietnam
NCT03678428
Phase 3
Completed
92 patients
The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic colorectal cancer liver metastases. The patients will be treated with ...
China
NCT05039944
Phase 2
Completed
7 patients
This multi-center, open label Phase II clinical study is performed in patients with unresectable or metastatic malignant tumors of the digestive system (colorectal cancer, gastric cancer). This study is investigating the safety and efficacy of SI-B00...
China
NCT04952753
Phase 2
Completed
204 patients
The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC.
Thi...
United States, Australia, Belgium, Canada, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan
NCT02942706
Phase 2
Completed
This study is try to evaluate the effect of cetuximab monotherapy as maintenance treatment, versus continuation after 8 courses of induction therapy with cetuximab plus standard chemotherapy regimen (FOLFIRI or mFOLFOX6?in metastatic colorectal cance...
Multiple
NCT04923620
Not Applicable
Completed
51 patients
Prospectively Investigate the effectiveness and safety of neoadjuvant cetuximab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS wild-type locally advanced rectal cancer
China
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
NCT04262635
Phase 3
Completed
This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without discontinuation for toxicity, ...
China
NCT05116891
Phase 1
Completed
40 patients
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
France, Spain
NCT05004350
Phase 2
Completed
107 patients
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC...
China
NCT04535401
Phase 1
Completed
10 patients
Medications:
5-Fluorouracil
Elimusertib
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first started to nearby tis...
United States
NCT04660812
Phase 1
Completed
227 patients
Medications:
5-Fluorouracil
AB680
Bevacizumab
Etrumadenant
Leucovorin
Oxaliplatin
Regorafenib
Zimberelimab
This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
United States, France, Italy, South Korea, Spain, United Kingdom
NCT04832776
Phase 2
Completed
160 patients
To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases
China
NCT04781270
Phase 3
Completed
308 patients
Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by conversion therapy. However, the optimal regimen of conversion therapy for RAS mutant patients has not been defined.
In this ...
China
NCT04761614
Phase 1
Completed
13 patients
This phase I trial is to find out the best dose, possible benefits, and/or side effects of riluzole and how well it works in combination with standard of care mFOLFOX6 and bevacizumab in treating patients with colorectal cancer that has spread to oth...
United States
NCT04158349
Phase 1
Completed
1 patients
This study is a prospective, multi-center, open-label phase I trial designed to determine the maximun tolerated dose of IP oxaliplatin when given in combination with mFOLFIRI.
United States
NCT04731467
Phase 1
Completed
79 patients
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C \& D) to evaluate the safety and tolerability of CM-24 in c...
United States, Israel, Spain
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
NCT04621370
Phase 2
Completed
48 patients
PRIME-RT is an open label, multi-centre phase II randomised trial with 1:1 allocation between arm A and arm B. The principal research question is whether the addition of durvalumab to FOLFOX chemotherapy and radiation treatment (either SCRT or LCRT) ...
NCT04553692
Phase 1
Completed
272 patients
Medications:
5-Fluorouracil
Aplitabart
Azacitidine
Bevacizumab
Birinapant
Docetaxel
Gemcitabine
Irinotecan
Leucovorin
Venetoclax
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematol...
United States, Australia, France, South Korea, Spain
NCT04735900
Not Available
Completed
Detection of progressive disease by neuropeptide Y (NPY) methylation in liquid biopsies in patients with RAS and BRAF wild-type, unresectable, metastatic colorectal cancer receiving first-line treatment FOLFOX/FOLFIRI and panitumumab.
Belgium
NCT04164069
Phase 1
Completed
9 patients
This phase Ib trial studies side effects and best dose of dasatinib in preventing oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancers who are receiving FOLFOX regimen with or without bevacizumab. Drugs used in chemothe...
United States
NCT04392479
Phase 3
Completed
202 patients
Optimization of second-line therapy with aflibercept, irinotecan (day1 or day 1,3), 5fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study.
France
NCT04543695
Phase 2
Completed
255 patients
A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
China
NCT03904043
Not Applicable
Completed
63 patients
The investigators' data from a phase I study of short course radiation therapy followed by chemotherapy showed 74% complete clinical response (cCR). Given the promising response rate, the investigators are evaluating short course radiation therapy (S...
United States
NCT04380337
Phase 2
Completed
38 patients
The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer. The objective is to learn if this treatment appr...
United States
NCT04276090
Not Applicable
Completed
21 patients
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy. This study aims to test the safety of hepatic artery infusion pump placement, a standard...
United States
NCT04130854
Phase 2
Completed
58 patients
Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.
United States
NCT04810585
Phase 4
Completed
153 patients
Based on the pervious data, aflibercept in combination with FOLFIRI is one of the effective 2nd line treatment option in advanced colorectal cancer. In this study, we prospectively assess the efficacy of 2nd line aflibercept in combination with FOLFI...
South Korea
NCT04513951
Phase 2
Completed
62 patients
The aim of this study is to evaluate the efficacy of mFOLFOXIRI plus cetuximab and avelumab as first line treatment of patients with initially unresectable and previously untreated RAS wild-type metastatic colorectal cancer (mCRC), in terms of Progre...
Italy
NCT04416854
Phase 3
Completed
627 patients
The aim of this trial is to evaluate the value of palliative primary tumor resection in colon cancer patients with initially unresectable metastases and a positive response to induction chemotherapy which depends on gene testing. The primary endpoint...
China
NCT04338191
Phase 3
Completed
638 patients
The current standard treatment for locally advanced rectal cancer is still fluorouracil-based neoadjuvant radiotherapy and chemotherapy followed by TME surgery, followed by adjuvant chemotherapy. Fluorouracil single-agent simultaneous sensitization o...
China
NCT04256707
Phase 1
Completed
This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines of treatment, with 1 line containing a checkpoint Inhibitor (CPI); ...
Israel
NCT04072198
Phase 2
Completed
73 patients
This is a multicentric single arm, open label trial. In this study patients candidated to a first line of chemotherapy for metastatic colorectal cancer will be treated with 8 cycles of folfoxiri plus bevacizumab plus nivolumab followed by a maintenan...
Italy
NCT03929666
Phase 2
Completed
74 patients
Medications:
5-Fluorouracil
Bevacizumab
Capecitabine
Cisplatin
Gemcitabine
Leucovorin
Oxaliplatin
ZW25
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestin...
United States, Canada, Chile, South Korea
NCT03829410
Phase 1
Completed
68 patients
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line treatment in adult partici...
United States
NCT03798626
Phase 1
Completed
167 patients
Medications:
5-Fluorouracil
Bevacizumab
Cabozantinib
Gevokizumab
Irinotecan
Leucovorin
Oxaliplatin
Paclitaxel
Ramucirumab
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal...
United States, Australia, Belgium, Canada, Chile, Czechia, Germany, Israel, Italy, Japan, Singapore,
NCT03300544
Phase 1
Completed
3 patients
This phase I trial studies the best dose and side effects of talimogene laherparepvec in combination with 5-fluorouracil, leucovorin, oxaliplatin, capecitabine, and chemoradiation before surgery in treating patients with rectal cancer that has spread...
United States
NCT03641976
Phase 2
Completed
RATIONALE: Recently, the importance of prognosis according to the location of the primary tumor in colorectal cancer has been raised. In the CALGB / SWOG 80405 study published in 2016, the addition of bevacizumab or cetuximab to the first line FOLFIR...
Republic of Korea
NCT03721653
Phase 2
Completed
218 patients
The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.
Italy
NCT03720678
Phase 1
Completed
44 patients
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants wi...
United States, Australia
NCT03690921
Phase 2
Completed
8 patients
Medications:
5-Fluorouracil
Cisplatin
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer. LET-IMPT is a type of radiation therapy that uses high e...
United States
NCT03751176
Phase 2
Completed
To estimate progression-free-survival at 6 months in subjects treated in first-line with panitumumab and FOLFOX and with wild type RAS mCRC (metastatic colorectal cancer) confirmed in liquid biopsies before starting second line treatment will be scre...
Spain
NCT03415763
Phase 3
Completed
764 patients
The purpose of this study is to evaluate the efficacy of adjuvant chemotherapy in patients with clinical stage III rectal cancer who received neoadjuvant chemoradiotherapy on the basis of postoperative pathological stage.
China
NCT03693807
Phase 2
Completed
35 patients
This study is being done to answer the following question:
Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of patients with metas...
United States
NCT03530267
Phase 2
Completed
124 patients
This is a controlled, open-label, randomized phase- II trial (1:1 randomization) investigating 5-FU + aflibercept and 5-FU + oxaliplatin in elderly and frail elderly patients with mCRC scheduled to receive first line treatment.
Germany
NCT03563157
Phase 1
Completed
2 patients
Medications:
5-Fluorouracil
ALT-803
Avelumab
Capecitabine
Cetuximab
Cyclophosphamide
ETBX-011
ETBX-021
ETBX-051
ETBX-061
GI-4000
GI-6207
GI-6301
Hank
Leucovorin
Nab-Paclitaxel
Oxaliplatin
Regorafenib
QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: This is a Phase 1b/2 study investigating the effect of NANT CRC vaccine vs regorafenib in subjects with CRC who were previously treated with SOC.
United States
NCT03645187
Phase 4
Completed
50 patients
The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer
Egypt
NCT03164655
Phase 2
Completed
20 patients
National trial, multicenter, randomized, phase II comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy (CT) to systemic chemotherapy alone in patients with liver-only colorectal metastases (CRLM) ...
France
NCT03503630
Phase 2
Completed
44 patients
The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.
Jordan, Lebanon
NCT03259035
Phase 2
Completed
58 patients
The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep...
United States, Canada
NCT03547999
Phase 2
Completed
17 patients
This is a multi-center Phase II randomized study. We plan to enroll 78 patients with biopsy-proven hepatic-limited metastatic colorectal cancer deemed resectable after multi-disciplinary discussion. Eligible patients must have confirmed isolated live...
United States
NCT03597581
Phase 1
Completed
89 patients
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal adenocarcinoma. The s...
United States
NCT03388190
Phase 2
Completed
80 patients
This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCR...
Norway
NCT03299660
Phase 2
Completed
37 patients
This trial is investigating the inclusion of avelumab post long-course chemo-radiotherapy in patients with resectable locally advanced rectal cancer. It is hypothesised that this may enhance the pathological and imaging response rates whilst potentia...
Australia
NCT03186326
Phase 2
Completed
132 patients
Medications:
5-Fluorouracil
Aflibercept
Avelumab
Bevacizumab
Cetuximab
Irinotecan
Leucovorin
Oxaliplatin
Panitumumab
Immune chekpoints (ICI) are evaluated in many digestive cancers. Certain types of cancer appear to be rather refractory to ICI such as colorectal cancers (CRC). However, the MSI CRC representing approximately 15% of the CRCs exhibits a high mutationa...
France
NCT03454620
Phase 1
Completed
53 patients
The purpose of the study is to assess the safety and tolerability of GC1118 in combination with irinotecan or FOLFIRI in order to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D)
South Korea
NCT03311750
Phase 2
Completed
A-REPEAT (Anti-Epidermal Growth Factor Receptor -EGFR- rechallenge and plasma genotyping of patients with advanced colorectal tumors) is a Greek, investigator-initiated, single arm open-label phase II study of anti-EGFR therapy rechallenge in combina...
Cyprus, Greece
NCT03300609
Phase 3
Completed
4 patients
This randomized trial studies how well panitumumab, leucovorin calcium, and fluorouracil after combination chemotherapy and panitumumab induction work in treating patients with RAS wild type colorectal cancer that has spread from where it started to ...
United States
NCT03414983
Phase 2
Completed
196 patients
This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).
United States, Canada, Japan, Puerto Rico, Spain
NCT03374254
Phase 1
Completed
116 patients
The purpose of this study is to determine safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) for the following combinations: pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg...
United States, Canada
NCT03365765
Phase 3
Completed
63 patients
This study will focus on postoperative patients of stage IIIB or stage IIIC colorectal cancer. These patients will start to accept chemotherapy in 3-4 weeks after operation, these patients were randomly divided into two groups, one group will accept ...
China
NCT03493061
Phase 2
Completed
60 patients
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis. The patients will be treated with systemic chemotherapy With i...
China
NCT03391934
Phase 3
Completed
234 patients
The study is designed as phase III, randomized, two armed, parallel, double blind (patient and assessor blinded), active controlled, and equivalency clinical trial with primary endpoint of Progression-Free Survival of Cetuximab® (produced by CinnaGe...
Iran
NCT05316818
Phase 2
Completed
64 patients
This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment of metastatic colorec...
Egypt
NCT03206151
Phase 3
Completed
520 patients
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as CMAB009, can block tumor growth in different ways. Giving combination ch...
China
NCT03314935
Phase 1
Completed
149 patients
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
United States, Belgium, United Kingdom
NCT03279289
Phase 2
Completed
170 patients
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an elderly population with met...
Spain
NCT03254394
Phase 1
Completed
26 patients
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen. Hypersensitivity to cold is the sensory hallmark of oxaliplatin-induced neuropathy, and it can predic...
United States
NCT03231722
Phase 3
Completed
435 patients
* The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patients.
* The phase III TRIBE trial recently demonstrated that FOLFOXIRI (5-fl...
Italy
NCT03202758
Phase 1
Completed
57 patients
Colo-rectal cancer is still one of the leading causes of cancer death worldwide. In France, approximately 40 500 new cases are diagnosed each year. With more than 17 500 deaths in France in 2011, colo-rectal cancer is responsible for more than 12% of...
France
NCT03184870
Phase 1
Completed
332 patients
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants ...
United States, Australia, Belgium, Canada, Germany, Spain
NCT03117972
Phase 2
Completed
54 patients
In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking. In this setting, a simple biological scoring system have recently been proposed, including LDH and CD138 binar...
France
NCT03000374
Phase 2
Completed
34 patients
Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging \[MRI\]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative Induction therapy w...
Spain
NCT03050814
Phase 2
Completed
30 patients
Background:
Colorectal cancer is a common cancer in the Unites States (U.S.) It causes the second most cancer-related deaths. The drug avelumab and vaccine Ad-CEA together help the immune system fight cancer.
Objective:
To test if avelumab and Ad-...
United States
NCT03914170
Not Applicable
Completed
70 patients
This retrospective study, will evaluate patient outcomes after triplet chemotherapy (FOLFIRINOX) (5 Fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a RAS (KRAS, NRAS (neuroblastoma rat sar...
France
NCT02967289
Phase 3
Completed
792 patients
The trial is a phase III, multicenter, open-labeled randomized trial comparing the association of 5-fluorouracil (5-FU), folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, and 5-FU (mFOLFOX 6) chemotherapy proto...
Canada, France
NCT02921256
Phase 2
Completed
363 patients
This randomized phase II trial studies how well veliparib or pembrolizumab work with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally...
United States, Puerto Rico
NCT03504618
Not Applicable
Completed
39 patients
Colon cancer with metastase in the diagnose time account for one significant rate and has a increasing trend. The treatment result of this patient group rests modest. The biological therapeutic treatment is still expensive for major part of Vietnames...
Vietnam
NCT03035253
Phase 1
Completed
16 patients
The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells...
United States
NCT02970916
Phase 2
Completed
100 patients
The purpose of this study is to assess FOLFIRI+aflibercept efficacy in patients with or without ACE polymorphisms in terms of Progression-free survival (PFS).
Spain
NCT02928224
Phase 3
Completed
702 patients
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E...
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Fran
NCT03288987
Phase 3
Completed
126 patients
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation. This trial was conducted to evaluate the efficacy and safety of bevacizumab (prod...
Iran
NCT05178745
Not Applicable
Completed
140 patients
Primary Objective:
-Evaluate the resection rate (R0/R1) in current practice for aflibercept in combination with irinotecan plus 5-fluorouracil (FOLFIRI) in patients treated for metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-cont...
NCT02613650
Phase 1
Completed
25 patients
This is a Phase 1b, open label, dose-finding study to determine the Maximum Tolerated Dose (MTD) of MEK162 in combination with mFOLFIRI, and to evaluate the response rate, clinical benefit rate and additional safety parameters of the treatment combin...
United States
NCT03167268
Phase 2
Completed
Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma. KRAS, NRAS, BRAF and PI3KA mutations and ERBB2 and MET amplification are responsible for most of the cases of pr...
Italy
NCT04718038
Not Applicable
Completed
60 patients
The aim of this study was to evaluate the efficacy and safety of continuing cetuximab combined with chemotherapy after first-line progression in wild-type KRAS,NRAS and BRAF colorectal cancer.
NCT02904031
Phase 2
Completed
* Few data are available about the treatment of metastatic colorectal cancer (mCRC) elderly patients with anti-EGFR agents in combination with chemotherapy. Up today, most of the available data are from retrospective/post-hoc analyses, making them di...
Italy
NCT02753127
Phase 3
Completed
1,253 patients
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previou...
United States, Australia, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy
NCT02641691
Phase 2
Completed
20 patients
The purpose of this research study is to look at how tumors responds to a short course of radiation (5 days) followed by 8 cycles of chemotherapy.
United States
NCT03253133
Phase 1
Completed
19 patients
This study determine the maximal tolerate dose
France
NCT02568046
Phase 1
Completed
10 patients
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
United States, Spain
NCT02726334
Phase 1
Completed
22 patients
The purpose of this study is to determine the maximum tolerated dose (which will be the dose recommended for a Phase 2 study), safety, tolerability and pharmacokinetic profile (study of movement of the drug within the body, including absorption and d...
Australia
NCT02508077
Phase 2
Completed
1 patients
Medications:
5-Fluorouracil
Panitumumab
This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal cancer that expresses the RAS and B-Raf proto-oncogene, serine/threonine...
United States
NCT02514278
Phase 3
Completed
218 patients
Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to decrease surgical morb...
France
NCT03031444
Phase 2
Completed
135 patients
This study was designed to analyze the prognosis and recurrence predictive factors of high risk patients (Clinical Risk Score≥3) of resectable colorectal liver metastasis.
The efficacy of perioperative chemotherapy plus cetuximab and chemotherapy ...
China
NCT02563002
Phase 3
Completed
307 patients
In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard...
NCT02640365
Phase 1
Completed
10 patients
MM-398 (also known as PEP02) is nanoliposomal encapsulated irinotecan: the liposomal formulation is designed to extend plasma circulation and to increase accumulation in the tumor through the enhanced permeability and retention (EPR) effect.
This st...
France
NCT02413853
Phase 2
Completed
This randomized phase II trial studies how well combination chemotherapy and bevacizumab with or without CBP/beta-catenin antagonist PRI-724 (PRI-724) works in treating patients with newly diagnosed colorectal cancer that has spread to other places i...
United States
NCT02439385
Phase 2
Completed
44 patients
Oral curcumin-containing supplement will be given to colorectal cancer patients with unresectable metastases who will be starting Avastin/FOLFIRI chemotherapy for up to completion of (or withdrawal from) chemotherapy.
NCT02482441
Phase 1
Completed
50 patients
This is an open-label Phase 1a/b dose-escalation study to assess the safety, tolerability, and PK of OMP-131R10 as a single agent for advanced solid tumors and in subjects with metastatic colorectal cancer.
United States
NCT02448810
Phase 2
Completed
115 patients
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy ...
United States
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
NCT02465593
Phase 1
Completed
32 patients
This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer).
There are 2 portions in this study.
* Escalation phase (Part Ib): A 3 + 3 dose escalation study design will be adopted in this phase to ...
Taiwan
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
NCT02375672
Phase 2
Completed
30 patients
This is a multi-institutional, single arm, open-label, phase II study, including a safety run-in cohort. No randomization or blinding involved.
United States
NCT02384759
Phase 2
Completed
117 patients
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.
France
NCT02291289
Phase 2
Completed
1,044 patients
Medications:
5-Fluorouracil
Atezolizumab
Bevacizumab
Capecitabine
Cetuximab
Cobimetinib
Leucovorin
Oxaliplatin
Pertuzumab
Trastuzumab
Vemurafenib
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have r...
Argentina, Belgium, Bosnia and Herzegovina, Brazil, Denmark, Egypt, France, Germany, Greece, Italy,
NCT02319304
Phase 2
Completed
3 patients
The purpose of this study is to assess the effects, both good and bad, of adding very low dose fractionated radiation therapy (LDFRT) to the pelvis, with FOLFOX chemotherapy prior to surgery. Standard pelvic radiation therapy given once a day (Monday...
United States
NCT02484833
Phase 3
Completed
607 patients
* To investigate whether cetuximab alone (given until progression or cumulative toxicity) after 8 cycles of FOLFIRI + cetuximab results in a non inferior Progression Free Survival when compared with continuous FOLFIRI + cetuximab (given until progres...
Italy
NCT02232152
Phase 1
Completed
19 patients
Medications:
5-Fluorouracil
This pilot phase I trial studies the side effects and best dose of CPI-613 when given together with fluorouracil in treating patients with colorectal cancer that has spread to other parts of the body and cannot be removed by surgery. CPI-613 may kill...
United States
NCT02340949
Phase 2
Completed
180 patients
This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in order to evaluate th...
NCT02270606
Phase 1
Completed
14 patients
Medications:
5-Fluorouracil
Oxaliplatin
This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has spread from where it s...
United States
NCT02305758
Phase 2
Completed
130 patients
This was a blinded, randomized, placebo-controlled Phase 2 multicenter study evaluating the efficacy and tolerability of veliparib plus irinotecan, fluorouracil, and leucovorin chemotherapy regimen (FOLFIRI) compared to placebo plus FOLFIRI in partic...
NCT02102022
Phase 1
Completed
140 patients
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
Phase 2: Assessment of the objective response rate (ORR), measured by RECI...
United States, China, Italy, South Korea, Taiwan, United Kingdom
NCT02181556
Phase 2
Completed
41 patients
One of the treatments generally used to treat this disease is a chemotherapy called FOLFIRI. The purpose of this study is to improve the efficacy of the chemotherapy by adding a protein, similar to immunoglobulins, aflibercept, and to assess their to...
France
NCT02135419
Phase 3
Completed
4,446 patients
Medications:
5-Fluorouracil
Imiquimod
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue ...
United States, Puerto Rico
NCT02414009
Phase 2
Completed
82 patients
Open-label, randomized, multicenter, Phase II trial designed to estimate the efficacy of CAPTEM versus FOLFIRI as second line treatment in MGMT methylated, RAS mutated advanced CRC patients who have progressed on or after first-line oxaliplatin conta...
Italy
NCT02173990
Phase 2
Completed
40 patients
The PULSAR trial is an international, investigator-initiated, single arm open-label phase II study. The aim of this study is to measure the clinical activity of the combination FOLFIRI-aflibercept in an homogeneous group of patients with metastatic c...
France
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases
NCT02162563
Phase 3
Completed
530 patients
Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been defined, and no consensus exist ...
Belgium, Netherlands
NCT02124148
Phase 1
Completed
167 patients
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to ano...
United States
NCT02017704
Phase 2
Completed
9 patients
This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).
United States
NCT02041481
Phase 1
Completed
26 patients
Medications:
5-Fluorouracil
Oxaliplatin
This phase I trial studies the side effects and best dose of MEK inhibitor MEK162 when given together with leucovorin calcium, fluorouracil, and oxaliplatin in treating patients with advanced metastatic colorectal cancer. MEK inhibitor MEK162 may sto...
United States
NCT02129257
Phase 2
Completed
73 patients
The AMALTHEA (Aflibercept MAintenance after first-Line THErapy with FOLFIRI+Aflibercept in metastatic colorectal cancer patients) trial is an investigator-initiated, single arm, open-label, phase II study. Patients with histologically proven metastat...
Greece
NCT02138617
Phase 2
Completed
100 patients
This study involves standard combination chemotherapy treatment for colon cancer, 5-Fluorouracil (5FU), leucovorin and irinotecan (known as FOLFIRI), plus bevacizumab (Avastin). The study is designed to test the FOLFIRI regimen based on certain chara...
United States
NCT02246049
Phase 2
Completed
69 patients
The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.
Japan
NCT01862003
Phase 2
Completed
24 patients
Recruitment to phase I of the PANTHER trial is complete.
Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
United Kingdom
NCT01991873
Phase 2
Completed
387 patients
This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy.
Eligible patients will be treated within a 12-week induction therapy. Those patients achieving CR/PR...
Germany
NCT02083653
Phase 2
Completed
254 patients
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epiderm...
United States, Austria, Belgium, France, Germany, Hungary, Italy, Poland, Russia, Spain
NCT02102789
Phase 3
Completed
142 patients
The primary objective of this study is to determine whether systemic chemotherapy combined with hepatic arterial infusion with floxuridine and dexamethasone can increase the complete resection rate (R0) and improve the overall survival in patients wi...
China
NCT02063529
Phase 2
Completed
101 patients
PURPOSE:
A primary aim of phase II FOCULM study is to explore whether cetuximab in combination with FOLFOXIRI as first treatment could improve surgical conversion in patients with KRAS/NRAS wild-type, unresectable liver - only metastases of colorect...
China
NCT02605044
Phase 3
Completed
123 patients
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
France, Singapore, United Kingdom
NCT01858662
Phase 2
Completed
4 patients
To analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with cetuximab combined with FOLFOX or FOLFIRI regimen in a prospective cohort (RAS and B-RAF WT tumors) and to correlate this response w...
Belgium
NCT02045030
Phase 2
Completed
14 patients
This is a Phase II multi-center exploratory study to identify biomarkers predictive of clinical response to aflibercept in patients with metastatic colorectal cancer who have failed first-line therapy, consisting of an oxaliplatin-containing regimen ...
Canada
NCT02033551
Phase 1
Completed
47 patients
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.
United States, Netherlands, Spain
NCT02404935
Phase 2
Completed
139 patients
National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free s...
France
NCT02009449
Phase 1
Completed
353 patients
Medications:
5-Fluorouracil
Capecitabine
Leucovorin
Nivolumab
Oxaliplatin
Paclitaxel
Pazopanib
Pegilodecakin
Pembrolizumab
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immuno...
United States
NCT01910610
Phase 3
Completed
464 patients
STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.
France, Ireland, Israel
NCT02000050
Phase 2
Completed
52 patients
Phase II study of up-front chemotherapy and neo-adjuvant shortcourse radiotherapy for resectable rectal carcinoma.
Study Design: Phase II, open-label, single-arm, multi-centre study.
STUDY PRODUCT,DOSE,ROUTE,REGIMEN AND DURATION OF ADMINISTRATION:
...
Italy
NCT01972490
Phase 4
Completed
241 patients
In this study, the investigators assessed the effect of avastin in combination with chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited metastases
China
NCT01508000
Phase 2
Completed
44 patients
Patients presenting with multiple innumerable liver metastases will probably never come to resection, however, for all others, including patients with numerous multiple metastases or large metastases,resection should be considered after limited chemo...
Austria, Belgium, France, Netherlands, Spain, Switzerland
NCT01721954
Phase 3
Completed
209 patients
This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus FOLFOX6m alone as first-lin...
United States, Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, Singapore,
NCT01853813
Phase 2
Completed
85 patients
Bevacizumab in combination with chemotherapy represents a standard of care for first-line treatment in patients with advanced colorectal cancer. Molecular predictive factors for bevacizumab efficacy have not yet been identified therefore selection of...
Italy
NCT01943786
Not Available
Completed
Medications:
5-Fluorouracil
Bevacizumab
Capecitabine
Cetuximab
Irinotecan
Leucovorin
Oxaliplatin
Panitumumab
Adenocarcinoma of the colon and rectum is a common, serious disease and it is the second cause of death from cancer in Spain.
The prognosis of CRC depends to a great extent on its stage when diagnosed. Patients with advanced disease, who present up ...
Spain
NCT01650428
Phase 2
Completed
20 patients
The purpose of this study is to evaluate the efficacy, toxicity and feasibility of FOLFOX/ bevacizumab and FOLFOXIRI/ bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.
United Kingdom
NCT01522612
Phase 2
Completed
5 patients
OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free Survival, compared with...
Belgium, Cyprus, Spain
NCT01814501
Phase 2
Completed
16 patients
Medications:
5-Fluorouracil
Panitumumab
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, c...
United States
NCT01765582
Phase 2
Completed
280 patients
This randomized, open-label, multicenter study will evaluate the efficacy and safety of folinic acid (leucovorin), 5-fluorouracil (5-FU), oxaliplatin, and irinotecan (FOLFOXIRI) / bevacizumab regimens (concurrent and sequential) versus folinic acid (...
United States
NCT01749956
Phase 2
Completed
39 patients
The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus afliberce...
United States
NCT01703390
Phase 2
Completed
47 patients
This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with...
Austria
NCT01740648
Phase 1
Completed
19 patients
Medications:
5-Fluorouracil
Trametinib
This phase I trial studies the side effects and best dose of trametinib when given together with fluorouracil and radiation therapy before surgery in treating patients with stage II-III rectal cancer. Trametinib may stop the growth of tumor cells by ...
United States
NCT01652196
Phase 2
Completed
56 patients
This phase II trial studies how well giving aflibercept together with combination chemotherapy works in treating patients with previously untreated colon or rectal cancer that is metastatic or locally advanced and cannot be removed by surgery. Aflibe...
United States
NCT01941953
Phase 2
Completed
50 patients
Medications:
5-Fluorouracil
Metformin
This is a phase II trial to evaluate efficacy and safety of Metformin and Fluorouracil in patients with metastatic colorectal cancer (CRC) who have progressed after Oxaliplatin and Irinotecan based chemotherapy.
Brazil
NCT01622543
Phase 2
Completed
109 patients
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
Canada
NCT01704703
Phase 2
Completed
72 patients
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and N...
Spain
NCT01652482
Phase 2
Completed
135 patients
This open-label, randomized, multicenter, Phase 2 study will evaluate the safety and efficacy of MEHD7945A when combined with FOLFIRI (folinic acid \[leucovorin\], 5-fluorouracil \[5-FU\], and irinotecan) chemotherapy as compared to cetuximab plus FO...
United States, Australia, Belgium, France, Germany, Italy, New Zealand, Romania, Spain, United Kingd
NCT01670721
Phase 3
Completed
175 patients
Primary Objective:
To evaluate the safety of aflibercept in participants with mCRC treated with irinotecan/5-Fluorouracil (5-FU) combination (FOLFIRI) after failure of an oxaliplatin-based regimen (participants similar to those evaluated in the VELO...
France
NCT01640405
Phase 3
Completed
350 patients
The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.
Spain
NCT01640444
Phase 2
Completed
240 patients
The purpose of the study is to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with RAS wild-type metastatic colorectal carcinoma and \< 3 circulating tumor ce...
Spain
NCT01715363
Phase 2
Completed
3 patients
The purpose of this study is to analyze the clinical tolerance of immediate preoperative chemotherapy in terms of toxicity and perioperative morbidity and mortality
France
NCT01588990
Phase 4
Completed
128 patients
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer. The study consists o...
Australia
NCT01515787
Phase 2
Completed
1,194 patients
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has ...
United States, Canada, Israel, Switzerland
NCT01621217
Phase 1
Completed
21 patients
Medications:
5-Fluorouracil
Cetuximab
* To establish maximum tolerated dose of the two cytotoxic drugs 5-fluoruracil and mitomycin C when given together with the antibody cetuximab in patients with locally advanced cancer in the anal region
* To evaluate acute toxicity
* To evaluate late...
Norway, Sweden
NCT01632722
Phase 2
Completed
79 patients
Early-stage colorectal cancer(CRC)is localized and resectable, but 20% of the patients have metastatic disease at the time of diagnosis and 50% of all patients eventually die of the disease. The most frequent site of colorectal metastases is the live...
South Korea
NCT01571284
Phase 3
Completed
781 patients
Primary Objective:
To provide metastatic colorectal cancer participants with access to aflibercept and to document the overall safety in these participants
Secondary Objective:
To document the Health-Related Quality of Life of aflibercept in this ...
United States, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Finland, Germany, Ireland, Israel,
NCT03084809
Phase 4
Completed
46 patients
Cytokine-induced killer cells (CIK) is an auxiliary antitumor treatment. The investigators aim to evaluate the clinical efficacy of chemotherapy combined with CIK in the treatment of postoperative colorectal cancer patients. And to provide useful ref...
NCT01571024
Phase 1
Completed
17 patients
The purpose of this study is to establish the safety and tolerability of BKM120 when combined with mFOLFOX6 and to define the maximum tolerated dose of BKM120 in this combination in advanced solid tumors including metastatic pancreatic cancer.
United States
NCT01516216
Phase 2
Completed
139 patients
This is a prospective, randomized, double-blind phase II trial to evaluate the efficacy and safety of two doses of vitamin D supplementation in combination with standard chemotherapy in participants with previously-untreated metastatic colorectal ade...
United States
NCT01674309
Phase 2
Completed
65 patients
The FOLFIRINOX protocol seems a promising protocol as attack treatment of a rectum cancer, with an objective response rate of about 70 %. This phase II is to investigate if this systematic attack chemotherapy could control at the same time the rectal...
France
NCT01263171
Phase 2
Completed
60 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-ra...
United Kingdom
NCT01643499
Phase 1
Completed
79 patients
Medications:
5-Fluorouracil
Oxaliplatin
This study is being done to determine the dose of a chemotherapy drug (irinotecan \[irinotecan hydrochloride\]) that can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs often used to treat gastrointestinal...
United States
NCT01523431
Phase 2
Completed
583 patients
The purpose of this study is to investigate the influence of dose selection of CPT-11 on toxicity, response and pharmacokinetics according to UGT1A1 genotype in colorectal cancer patients.
China
NCT03085992
Phase 2
Completed
49 patients
This study includes patients affected by advanced and resectable rectal adenocarcinoma. It provides an induction chemotherapy with FOLFOXIRI regimen plus Bevacizumab followed by Chemoradiotherapy plus Bevacizumab. Surgery with total mesorectal incisi...
Italy
NCT03532711
Not Applicable
Completed
264 patients
Medications:
5-Fluorouracil
Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors understand the effect of che...
NCT01490866
Phase 2
Completed
70 patients
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
United States
NCT01478594
Phase 2
Completed
265 patients
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in...
United States, Australia, Austria, Belgium, Canada, Czechia, Finland, Hungary, Italy, Netherlands, S
NCT01479465
Phase 2
Completed
266 patients
The primary objective of this study is to compare the additive efficacy of SIM versus placebo in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as measured by improvement in progression-free survival (PFS) in parti...
United States, France, Germany, Italy, Poland, Russia, Spain
NCT01399684
Phase 2
Completed
127 patients
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to estimate the efficacy of MEGF0444A treatment to disease progression, combined with oxaliplatin + folinic acid + 5-Fluorouracil (mFOLFOX-6) + bevacizumab t...
United States, Australia, Belgium, Poland, Spain
NCT01347645
Phase 1
Completed
82 patients
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
The purpose of the Phase II portion is to find out how safe the study drug is when taken at the high...
United States, Argentina, Australia, Brazil, Russia, Ukraine
NCT01418222
Phase 2
Completed
194 patients
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.
United States
NCT01420874
Phase 1
Completed
15 patients
The purpose of this research study is for the participant to give their own T cells (a type of blood cell in the body that can fight infections and possibly cancer) to them after they have been removed, grown in a lab, and then coated with an experim...
United States
NCT01383707
Phase 2
Completed
77 patients
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid, 5-Fluorouracil \[5-FU\] and o...
Italy
NCT01384994
Phase 2
Completed
Medications:
5-Fluorouracil
Bevacizumab
Capecitabine
Cetuximab
Irinotecan
Leucovorin
Oxaliplatin
Panitumumab
Up to 50% of patients with colorectal cancer (CRC) develop liver metastasis during the course of their disease. In 30-40% of patients metastasis is confined to the liver. In these patients R0-resection of metastases may contribute to marked improveme...
Germany
NCT01374425
Phase 2
Completed
376 patients
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated with bevacizumab plus le...
United States, Canada, Estonia, Ireland, Norway, Portugal, Switzerland
NCT01383343
Phase 1
Completed
17 patients
Medications:
5-Fluorouracil
Bevacizumab
This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with bevacizumab, irinotecan hydrochloride, leucovorin calcium, and fluorouracil in treating patients with colorectal cancer that has spread to other ...
United States
NCT01900717
Phase 2
Completed
102 patients
To evaluate tolerance to and efficacy of bevacizumab in the treatment of MCRC in elderly patients, we propose a phase II randomised study comparing a chemotherapy + bevacizumab arm with a chemotherapy alone arm in the first-line treatment of MCRC in ...
France
NCT01417494
Phase 2
Completed
102 patients
RATIONALE: Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoc...
France
NCT01376453
Phase 1
Completed
18 patients
Medications:
5-Fluorouracil
Sorafenib
The main purpose of this study is to find the maximum tolerable dose of sorafenib when administered along with another drug called 5-Fluorouracil (5-FU) and to find out more about whether these drugs, along with radiation, can help people with rectal...
United States
NCT01362361
Phase 2
Completed
54 patients
The purpose of this study:
To explore the comparative effectiveness of BIBF 1120 in terms of :
* Progression-free survival (PFS), objective response, overall survival
* Evaluate and compare safety
Germany
NCT01321957
Phase 2
Completed
250 patients
The primary objective of this study is to evaluate the efficacy of Irinotecan in combination with FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone in the first-line treatment of patients with metastatic colorectal cancer.
Germany
NCT01375816
Phase 2
Completed
55 patients
RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated irinotecan hydrochloride PEP02, irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells...
France
NCT01333709
Phase 2
Completed
150 patients
The purpose of this study is to determine whether the tailored management of locally advanced rectal carcinoma can improve the oncologic and functional outcome.
France
NCT01298570
Phase 2
Completed
181 patients
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously treated with a FOLFOX reg...
United States, Ireland
NCT01328171
Phase 2
Completed
93 patients
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups:
Experiment...
Germany
NCT01326000
Phase 2
Completed
169 patients
This randomized, multicenter, open label study will evaluate the safety and efficacy of RO5083945 in combination with FOLFIRI as compared to FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with metastatic colorectal cance...
United States, Australia, Belgium, France, Germany, Italy, Poland, Spain, United Kingdom
NCT01205022
Phase 1
Completed
3 patients
Medications:
5-Fluorouracil
Bevacizumab
RATIONALE: Radiolabeled monoclonal antibodies can find tumor cells and either kill them or carry tumor-killing substances to them without harming normal cells. Giving radioactive substances together with antibodies may be effective treatment for some...
United States
NCT01327612
Phase 2
Completed
12 patients
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose pr...
United States, Poland, Spain
NCT01378143
Phase 2
Completed
53 patients
The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS in combination with standard of care as a second line treatment in subjects with unresectable and locally recurrent or metastatic colorectal cancer.
Canada
NCT01320683
Phase 2
Completed
1 patients
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer. Drugs used in chemother...
United States
NCT01286818
Phase 1
Completed
6 patients
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with irinotecan, levofolinate, and 5...
Japan
NCT03428529
Phase 2
Completed
63 patients
Medications:
5-Fluorouracil
A randomized two-arm study comparing preoperative CRT using oral capecitabine versus bolus 5-FU/LV concomitant to external beam radiation (50.5 Gy/28 fractions) for locally advanced rectal cancer. Main outcome was clinical response assessed using MRI...
NCT01276379
Phase 2
Completed
221 patients
Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures (less than 4 liver nodules and less than 5 cm) and are suitable fo...
Spain
NCT01277406
Phase 1
Completed
17 patients
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of ad...
Germany
NCT01279681
Phase 3
Completed
32 patients
This randomized phase III trial studies how well combination chemotherapy plus bevacizumab with or without oxaliplatin works in treating older patients with colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy wor...
NCT01183780
Phase 3
Completed
1,072 patients
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
United States, Argentina, Australia, Austria, Belgium, Brazil, Czechia, Denmark, Finland, France, Ge
NCT01322178
Phase 2
Completed
The aim of this study is to explore whether cetuximab in combination with mFOLFOX6 as treatment could improve the resection rate in patients with KRAS wild-type, unresectable liver metastases of mCRC.
China
NCT01251536
Phase 2
Completed
108 patients
The purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study the molecular signatur...
Austria, Belgium, France, Hungary, Spain
NCT01274624
Phase 1
Completed
36 patients
This is a Phase 1 dose-escalation study with three dose levels to determine the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab.
United States
NCT01442649
Phase 2
Completed
133 patients
The main objective is to evaluate progression-free survival (PFS) at 4 months.
The secondary objectives are to evaluate the objective response rate (OR) (= complete responses (CR) and partial responses (PR)) according to the RECIST v1.1 criteria, th...
France
NCT01226719
Phase 2
Completed
15 patients
In this Phase II study the investigators plan to determine the overall response rate (ORR) of the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with liver-only metastatic KRAS wild-type colorectal cancer.
United States
NCT01288339
Phase 2
Completed
78 patients
To estimate the progression free survival for subjects treated with panitumumab in combination with a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX) as first-line chemotherapy regimen for subjects with metastatic c...
Spain
NCT01238965
Phase 1
Completed
7 patients
Medications:
5-Fluorouracil
Panobinostat
Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killi...
United States
NCT01228734
Phase 3
Completed
553 patients
The purpose of this study was to assess whether the progression free survival (PFS) time with FOLFOX-4 plus cetuximab is longer than that with FOLFOX-4 alone as first-line treatment for mCRC in Chinese subjects with RAS wild-type tumors.
China
NCT01206530
Phase 1
Completed
50 patients
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab. In toxicity terms, the investigators previous studies lead them t...
United States
NCT01260415
Phase 2
Completed
This is a phase II study to assess whether treatment with chemotherapy drugs FOLFOX (5-Fluorouracil (5FU), Oxaliplatin (Eloxatin) and Leucovorin (Folinic Acid)) or FOLFIRI (5-Fluorouracil (5FU), Irinotecan (Camptosar) and Leucovorin (Folinic Acid))an...
Canada
NCT01161316
Phase 2
Completed
194 patients
The purpose of the study is to evaluate the efficacy and safety of the combination of mFOLFOX-6 plus cetuximab for 8 cycles followed by mFOLFOX-6 plus cetuximab or single agent (s/a) cetuximab as maintenance therapy in patients (pts) with metastatic ...
Spain
NCT01167725
Phase 3
Completed
340 patients
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating mitomycin C to several degrees above normal body temperature and infusing it into t...
United States
NCT01183663
Phase 1
Completed
180 patients
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer. The safety of the drug combinations will also be studied.
United States
NCT01197664
Phase 1
Completed
2 patients
Medications:
5-Fluorouracil
Paricalcitol
This randomized pilot clinical trial studies the side effects of giving paricalcitol together with fluorouracil and radiation therapy in treating patients with rectal cancer that can be removed in surgery. Paricalcitol may help rectal cancer cells be...
United States
NCT01198548
Phase 2
Completed
10 patients
This phase II trial is studying how well giving high-dose cholecalciferol works in treating patients receiving combination chemotherapy and bevacizumab as first-line therapy for metastatic colorectal cancer. Cholecalciferol during treatment may delay...
United States
NCT01111604
Phase 2
Completed
158 patients
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard chemotherapy plus ic...
United States, Canada
NCT01363843
Phase 2
Completed
39 patients
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery. Patients have recently been di...
United States
NCT01124630
Phase 1
Completed
21 patients
Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]) in subjects with metastatic colorectal cancer (CRC) who have failed first-line treatment that was not irinotecan-based.
United States
NCT01205711
Phase 2
Completed
111 patients
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zibotentan may be ...
United Kingdom
NCT01133990
Phase 1
Completed
5 patients
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
The purpose of the Phase II portion is to find out how safe the study drug is when taken at the high...
United States, Australia, India, Russia, Ukraine
NCT01085331
Phase 1
Completed
16 patients
The research trial is testing the experimental treatment pimasertib (MSC1936369B) in combination with FOLFIRI, as second-line treatment in metastatic K Ras mutated colorectal cancer subjects. The study will be run in two parts:
Part 1, or Safety Run...
Belgium, Italy, Spain
NCT01358812
Phase 2
Completed
37 patients
The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy compared to FOLFIRI in a phase III trial. Panitumumab with oxaliplatin- or irinotecan-based doublets is feasible and associated with improved activity in KRAS codon 12-13 wild-type ...
Italy
NCT01280643
Not Applicable
Completed
3 patients
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, oxaliplatin, capecitabine, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from d...
United States
NCT01080547
Phase 3
Completed
374 patients
A new notion"Fast Track Multi-Discipline Treatment" for colorectal cancer is thought with several benefits such as shorter hospitalization stay and less costs. This randomized study aims to compare the differences between conventional and Fast Track ...
China
NCT00952029
Phase 2
Completed
492 patients
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may st...
France
NCT01269229
Phase 2
Completed
32 patients
The purpose of this study is the increase of resection rate of primary cancer in rectal after short course radiotherapy without interrupt chemotherapy schedule during the period of chemotherapy. The subject should have the pathologically confirmed fo...
South Korea
NCT01183494
Phase 1
Completed
17 patients
This study is being done to determine the maximum dose of a certain chemotherapy drug (irinotecan) that can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs typically used to treat cancer of the colon and r...
United States, Italy
NCT01274962
Phase 2
Completed
180 patients
This study is proposed to evaluate whether giving part of the chemotherapy prior to radiotherapy and surgery (as opposed to standard of care, which involves giving all the chemotherapy after radiotherapy and surgery) for patients with node positive o...
Canada
NCT00851045
Phase 2
Completed
17 patients
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer
United States, Argentina, Italy
NCT00959647
Phase 2
Completed
19 patients
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were elig...
United States
NCT00967616
Phase 2
Completed
100 patients
This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America. Adult subjects with metastatic colorectal cancer (CRC) who failed fi...
United States, Argentina, Brazil, Chile, Peru
NCT01030042
Phase 3
Completed
110 patients
Primary Objectives:
Aim of this study is to compare the efficacy and safety of two different sequences of chemotherapeutic agents in order to optimize the treatment of patients with metastatic colorectal cancer progressed to a first line chemotherap...
Italy
NCT00973609
Phase 3
Completed
853 patients
Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction treatment for 24 weeks wi...
Germany
NCT01077739
Phase 2
Completed
75 patients
This open-label single arm study will evaluate the efficacy and safety of Avastin added to XELOX or FOLFOX in patients with metastatic colorectal cancer and disease progression on 1st line therapy with FOLFIRI plus Avastin. Patients will receive eith...
Belgium
NCT00975897
Phase 2
Completed
3,240 patients
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors select the best treatment for pati...
United Kingdom
NCT00942266
Phase 2
Completed
58 patients
Medications:
5-Fluorouracil
Vorinostat
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth of tumor cells, either...
United States
NCT00932438
Phase 1
Completed
70 patients
This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in patients with colorecta...
United States, Argentina
NCT01437618
Not Applicable
Completed
15 patients
The purpose of this study is to prospectively verify if FOLFOXIRI plus bevacizumab as first-line treatment could be considered a promising approach to improve the outcome of BRAF mutant metastatic colorectal cancer patients
Italy
NCT00958737
Phase 3
Completed
2,000 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giv...
France
NCT00885885
Phase 2
Completed
80 patients
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.
Spain
NCT00851136
Phase 1
Completed
9 patients
This will be a multicenter, open-label study enrolling a total of up to 23 patients.
NCT00904839
Phase 2
Completed
128 patients
The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.
Belgium, France, Germany, Italy, Spain
NCT00873756
Phase 1
Completed
23 patients
This is a multicenter, open-label study enrolling a total of up to 23 patients.
United States
NCT00890305
Phase 2
Completed
171 patients
This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX chemotherapy (FOLFOX4 or mFO...
United States, Bulgaria, India, Peru, Puerto Rico, Romania
NCT00819780
Phase 2
Completed
285 patients
The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-...
United States, Belgium, Canada, Germany, Italy, Spain
NCT01068132
Phase 2
Completed
54 patients
Italian, multicentre, non comparative trial in patients with advanced Colorectal Cancer(CRC)and KRAS wild-type, defined by molecular evaluation.
Patients will receive Cetuximab + FOLFIRI until disease progression, unacceptable toxicity developed or ...
Italy
NCT00873275
Phase 1
Completed
11 patients
RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such a...
United States
NCT00866944
Phase 2
Completed
35 patients
The purpose of this study is to determine the effect of adecatumumab alone or following FOLFOX in patients with R0 resected liver metastases from CRC (colorectal carcinoma) and to compare the effect to FOLFOX alone.
France, Germany
NCT00889343
Phase 2
Completed
101 patients
The purpose of this study is to determine whether sorafenib in combination with chemotherapy has a positive effect on time to progression of the tumor or death for the treatment of large bowel cancer that has already progressed during a first chemoth...
Germany
NCT00865709
Phase 2
Completed
198 patients
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
United States, Belgium, Hungary, Italy, Poland, Romania, Russia, Spain, Ukraine, United Kingdom
NCT00778830
Phase 1
Completed
289 patients
This is an open-label, non-randomized, multicenter Phase II study evaluating folinic acid + fluorouracil + irinotecan (FOLFIRI) plus cetuximab (Erbitux) or folinic acid + fluorouracil + oxaliplatin (FOLFOX) plus cetuximab as first-line therapy of pat...
Singapore
NCT00719199
Phase 1
Completed
21 patients
Open-label phase 1b trial. Study treatment will be administered in 3 week cycles.
There are two distinct parts in this study:
* Part 1: Dose escalation from IMO-2055
* Part 2: Once a recommended phase 2 dose is found additional tolerability and pha...
United States
NCT00807911
Phase 2
Completed
322 patients
The purpose of this study is to evaluate the disease-free survival in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy with fluoropyrimidines and surgery followed by adjuvant combination chemotherapy with oxali...
South Korea
NCT00752570
Phase 2
Completed
144 patients
This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.
NCT00779311
Phase 1
Completed
8 patients
This research study is being performed at approximately 3 sites associated with Accelerated Community Oncology Research Network, Inc. (ACORN). Approximately 45 subjects will take part in this study.
In this study, everyone will receive the same dose...
United States
NCT00755118
Phase 2
Completed
24 patients
The aim of this study is to evaluate the efficacy of the effective drugs in a alternating chemotherapy schedules in pretreated patients with mCRC, who have received all effective drugs.
Greece
NCT00707889
Phase 2
Completed
159 patients
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
United States, Australia, Belgium, Brazil, Canada, Czechia, Greece, New Zealand, Poland, Portugal, R
NCT00780169
Phase 1
Completed
16 patients
The purpose of this study is to assess the safety, the maximum tolerated dose and the recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan, and 5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) as first-line tr...
Canada
NCT00806663
Phase 2
Completed
22 patients
This is an open label single arm prospective multicenter Phase II study in around 20 patients. The primary objective of this study is to evaluate whether the addition of sunitinib to FOLFIRI results in a significant reduction of tumor vessel permeabi...
Germany
NCT00719797
Phase 3
Completed
509 patients
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such...
Italy
NCT00721916
Phase 2
Completed
107 patients
This is a randomized, multicenter study designed to evaluate the progression free survival of the SOL group (S-1, Leucovorin, and Oxaliplatin) compared with the mFOLFOX6 group (5-FU, l-LV and Oxaliplatin) as first-line treatment of patients with meta...
Japan
NCT00654160
Phase 1
Completed
7 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination c...
United States
NCT00720512
Phase 3
Completed
184 patients
RATIONALE: Drugs used in chemotherapy, such as irinotecan, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such...
Italy
NCT00660153
Phase 1
Completed
30 patients
The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with colorectal cancer and other gastrointestinal cancers. Tivozanib (AV-951) is a targeted anti-angiogenesis agent that has demonstrated acceptable tolerability in ...
Netherlands
Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis
NCT00743678
Phase 2
Completed
73 patients
An innovative therapeutic strategy to increase the complete resection rate is of utmost importance in order to enhance survival in colorectal cancer patients with unresectable liver-only metastasis. Therefore, the investigators propose a prospective ...
South Korea
NCT00636610
Phase 2
Completed
199 patients
This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression. Patients received either FOLFO...
NCT00668863
Phase 2
Completed
71 patients
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
Japan
NCT00611858
Phase 2
Completed
13 patients
Medications:
5-Fluorouracil
Cetuximab
The standard treatment for rectal cancer is to receive the chemotherapeutic drug 5-fluorouracil (5-FU) with radiation therapy before having surgery to remove the rectal cancer. This is known as neoadjuvant chemoradiotherapy. The purpose of this resea...
United States
NCT00613080
Phase 2
Completed
79 patients
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor ...
United States, Canada
NCT00609622
Phase 2
Completed
191 patients
This study will compare the safety and efficacy of sunitinib in combination with FOLFOX versus bevacizumab in combination with FOLFOX for the treatment of patients with metastatic colorectal cancer who have not been treated before.
United States, Denmark, Germany, Japan
FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor
NCT00660582
Phase 2
Completed
152 patients
The Nordic FLOX-regime consists of a combination of bolus 5-FU, leukovorin and oxaliplatin (Eloxatin®). Cetuximab (Erbitux®) is an antibody against the epidermal growth factor receptor (EGFR). The combination of FLOX and weekly Erbitux has been inv...
Denmark, Norway, Sweden
NCT00615056
Phase 2
Completed
171 patients
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients wit...
United States, Canada, France, Italy, Japan, Poland, South Korea, Spain
NCT00642746
Phase 2
Completed
16 patients
The purpose of this study is to see if alternating chemotherapy with erlotinib increases tumor shrinkage in people with metastatic colorectal cancer. The investigator will also be studying the side effects (good and bad) of alternating chemotherapy w...
United States
NCT00749450
Phase 3
Completed
6,088 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination...
United Kingdom
NCT00769405
Phase 3
Completed
264 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether systemic ch...
France
NCT00612586
Phase 2
Completed
117 patients
This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV + ...
United States, Austria, France, Germany, Italy, Puerto Rico
NCT00479752
Phase 2
Completed
151 patients
To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly.
Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Greece, Hungary, Israel, Latvia, Romani
NCT00631410
Phase 1
Completed
12 patients
To assess the safety and tolerability of sunitinib when administered in combination with modified FOLFOX6 in Japanese patients with metastatic colorectal cancer in the first-line treatment setting.
Japan
NCT00580073
Phase 2
Completed
6 patients
This study involves the use of Oxaliplatin, 5-Fluorouracil (5-FU), Leucovorin and Cetuximab, which are all medicines approved by the Food and Drug Administration (FDA) and are commercially available. This treatment regimen will possibly be combined w...
United States
NCT01878422
Phase 3
Completed
376 patients
Study Design: This is a pragmatic study on the management strategy for patients with metastatic colorectal cancer (CRC) who are candidates for CT, independently of any previous adjuvant therapy received. The aim of this study is to define the role of...
Italy
NCT00561470
Phase 3
Completed
1,226 patients
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) a...
United States, Argentina, Australia, Austria, Belgium, Brazil, Chile, Czechia, Denmark, Estonia, Fra
NCT00541125
Phase 2
Completed
20 patients
RATIONALE: G-CSF may prevent or control neutropenia caused by first-line therapy in patients with metastatic colorectal cancer.
PURPOSE: This phase II trial is studying how well G-CSF works in preventing neutropenia during first-line treatment with ...
NCT00541112
Phase 2
Completed
19 patients
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cel...
France
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
NCT00865189
Phase 2
Completed
91 patients
This study will assess the efficacy and safety of two different neoadjuvant treatment approaches including bevacizumab in newly diagnosed participants with high risk locally advanced rectal cancer. Participants will be randomized into one of two trea...
France
NCT00625651
Phase 1
Completed
202 patients
This phase 1/2, multi-center, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with mFOLFOX6 and bevacizumab compared with mFOLFOX6 and bevacizumab alone in subjects with prev...
United States
NCT01271166
Phase 1
Active
10 patients
This is a Phase I, dose finding, multicentre study evaluating the maximal tolerated dose of Glivec® in combination with mFOLFOX-Avastin®. Patients will be enrolled into each dose level in 3 patient cohorts. Additional cohorts will be enrolled, or d...
Australia
NCT00497497
Phase 1
Completed
20 patients
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal cancer (mCRC) who have pro...
NCT00557102
Phase 2
Completed
24 patients
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used ...
France
NCT00640081
Phase 2
Completed
169 patients
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some bl...
Cyprus, United Kingdom
NCT00642577
Phase 3
Completed
214 patients
This 2 arm study will assess the efficacy and safety of Avastin in combination with irinotecan + 5-fluorouracil/folinic acid, versus irinotecan + fluorouracil/folinic acid alone, as first line treatment in Chinese patients with metastatic colorectal ...
China
NCT00689624
Phase 2
Completed
30 patients
This study will evaluate the efficacy of FOLOFOXIRI plus Cetuximab combination in young patients with good performance status with unresectable metastatic colorectal cancer.
Greece
NCT00457691
Phase 3
Completed
768 patients
The purpose of the study is to evaluate the safety and efficacy of FOLFIRI (Irinotecan, Leucovorin and 5 Fluorouracil) chemotherapy when combined with sunitinib or FOLFIRI chemotherapy without adding sunitinib as the first line treatment of patients ...
Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Col
NCT00499369
Phase 3
Completed
72 patients
This randomized phase III trial is studying giving irinotecan and cetuximab together with bevacizumab to see how well it works compared with giving irinotecan and cetuximab alone in treating patients with metastatic colorectal cancer that progressed ...
United States
NCT00494221
Phase 1
Completed
172 patients
This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe. Once this part is complete and it is decided that i...
Japan
NCT00537823
Phase 2
Completed
9 patients
The purpose of this study is to determine the effect of short-duration pre-operative FOLFOX based therapy on postoperative problems after liver surgery for patients with metastatic colorectal cancer.
United States
NCT00508404
Phase 2
Completed
154 patients
To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leu...
NCT00766142
Phase 2
Completed
18 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuxima...
France
NCT00462501
Not Applicable
Completed
35 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizu...
United States
NCT00500292
Phase 2
Completed
109 patients
The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine con...
France, Hungary, Slovakia, South Korea, Spain, Taiwan
NCT00454116
Phase 2
Completed
106 patients
The purpose of this study is to assess the efficacy and safety of 2 doses of ZACTIMA™ (ZD6474) in combination with FOLFIRI vs FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyr...
United States, Argentina, Norway, South Korea, Spain, United Kingdom
NCT00316888
Phase 2
Completed
63 patients
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Drugs u...
United States
NCT00527111
Phase 2
Completed
139 patients
Medications:
5-Fluorouracil
Cetuximab
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
United States
NCT00439517
Phase 2
Completed
302 patients
This is an exploratory study to compare activity and safety in 400 patients with previously untreated metastatic carcinoma of the colon treated with UFOX (a combination regimen of UFT® (Tegafur plus Uracil), Oxaliplatin, Folinic Acid) plus Cetuximab...
Argentina, Australia, Austria, Belgium, Brazil, France, Germany, Greece, Hong Kong, Israel, Italy, M
NCT00440310
Phase 3
Completed
483 patients
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver metastases, and to demonstra...
Austria, Bosnia and Herzegovina, Croatia, Germany, India, Italy, Latvia, Poland, Romania, Russia, Se
NCT00467142
Phase 2
Completed
62 patients
Medications:
5-Fluorouracil
Bevacizumab
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizum...
France
NCT00628810
Phase 2
Completed
86 patients
Medications:
5-Fluorouracil
Bevacizumab
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some ...
France
NCT01481545
Phase 2
Completed
62 patients
The purpose of this study is to evaluate the use of chemotherapy, radiation therapy and bevacizumab before surgery in patients with locally advanced rectal cancer (LARC).
NCT00469443
Phase 3
Completed
330 patients
This phase III study will compare two combinations of irinotecan, Folfiri versus Xeliri, with the addition of Avastin as 1st line treatment of colorectal cancer.
Greece
NCT00423293
Phase 2
Completed
63 patients
Medications:
5-Fluorouracil
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as fluorouracil and mitomycin C, work in differen...
United States, Canada
NCT00418938
Phase 2
Completed
266 patients
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed first-line oxaliplatin-ba...
NCT00411450
Phase 2
Completed
116 patients
The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic colorectal cancer (m...
NCT00399035
Phase 3
Completed
1,254 patients
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal canc...
Argentina, Australia, Brazil, Bulgaria, China, Czechia, Germany, Hungary, India, Philippines, Poland
NCT00387387
Phase 1
Completed
50 patients
This study will test the safety of treating colorectal cancer with a combination of drugs. The current standard treatments of FOLFOX6 or CapeOx will be give in combination with the GSK investigational drug pazopanib.
India, United Kingdom
NCT00385021
Phase 2
Completed
20 patients
To determine efficacy in the delivery of chronomodulated chemotherapy.
United States
NCT00544349
Phase 2
Completed
45 patients
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuxima...
France
NCT00422864
Phase 2
Completed
26 patients
This trial is a single-arm study for patients presenting with both local and metastatic adenocarcinoma of rectum. The aims of the trial are (1) to determine the tolerability rate, and (2) to determine toxicity rates, pelvic and distant response rates...
Australia
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
NCT00324415
Phase 2
Completed
45 patients
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tu...
United States
NCT00384176
Phase 2
Completed
1,814 patients
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
United States, Australia, Austria, Belgium, Canada, Czechia, Egypt, Finland, France, Germany, Hungar
NCT00364013
Phase 3
Completed
1,183 patients
The purpose of this study is to determine the treatment effect of panitumumab in combination with FOLFOX compared to FOLFOX alone as first line therapy for metastatic colorectal cancer
NCT00349336
Phase 3
Completed
64 patients
This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil). Patients randomized...
Australia, Canada, New Zealand
NCT00321685
Phase 2
Completed
57 patients
This phase II trial studies how well giving bevacizumab, radiation therapy, and combination chemotherapy works in treating patients who are undergoing surgery for locally advanced nonmetastatic rectal cancer. Monoclonal antibodies, such as bevacizuma...
United States
NCT00671372
Phase 1
Completed
42 patients
This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab (only for Cohort 6 subjects who have not received prior bevacizumab thera...
United States
NCT00339183
Phase 3
Completed
1,186 patients
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
NCT00303628
Phase 3
Completed
355 patients
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can bl...
United States, Canada, Peru, Puerto Rico
NCT00307736
Phase 1
Completed
32 patients
The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combin...
United States
NCT00332163
Phase 2
Completed
95 patients
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.
NCT00423696
Phase 2
Completed
145 patients
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizum...
France
NCT00449163
Phase 2
Completed
25 patients
RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizuma...
United States
NCT00308516
Phase 2
Completed
66 patients
This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation, and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and bevacizumab. Fluorouracil (FU) has proven to be an effective and safe...
United States
NCT00321828
Phase 2
Completed
90 patients
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizu...
United States
NCT00602329
Phase 2
Completed
5 patients
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizu...
United States
NCT00786643
Phase 2
Completed
48 patients
The purpose of this study is to evalute the response and toxicity of metastatic colorectal cancer patients to the regimen of gamma interferon added to bolus and infusional 5-fluorouracil and leucovorin (GFL) with or without bevacizumab.
United States
NCT00278889
Phase 2
Completed
215 patients
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer
Austria, Belgium, Canada, Czechia, France, Germany, Italy, Spain, United Kingdom
NCT00268463
Phase 3
Completed
22 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, capecitabine, and floxuridine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hepatic arterial infusion uses a cathe...
United States
NCT00305188
Phase 3
Completed
879 patients
Primary Objective : Compare the risk of occurrence of Grade3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin between treatment group and placebo group.
Main Secondary Objective : Compare the response rate ...
United States, Argentina, Australia, Brazil, Canada, Chile, Germany, Hungary, Italy, Poland, Portuga
NCT00343408
Phase 1
Completed
31 patients
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killi...
Canada
NCT00265850
Phase 3
Completed
2,334 patients
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer.
RATIONALE: Monoclonal antibodie...
United States, Canada
NCT00265811
Phase 3
Completed
2,559 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin, or fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination c...
France
NCT00559741
Phase 2
Completed
80 patients
Medications:
5-Fluorouracil
Cetuximab
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used ...
France
NCT00098787
Phase 2
Completed
247 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such...
United States
NCT00413322
Phase 1
Completed
35 patients
Medications:
5-Fluorouracil
Belinostat
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when g...
United States
NCT00556413
Phase 2
Completed
42 patients
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used ...
France
NCT00252564
Phase 3
Completed
247 patients
The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.
United States
NCT00268333
Phase 2
Completed
39 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-ra...
France
NCT00499850
Phase 1
Completed
18 patients
A Phase I,open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma.
Australia
NCT00507091
Phase 1
Completed
24 patients
A Phase I open label study to asses the safety and tolerability of ZD6474 in combination with Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as first or second line therapy in patients with metastatic colorectal adenocarcinoma.
Belgium, United Kingdom
NCT00193219
Phase 2
Completed
36 patients
This trial will evaluate the combination of modified infusional 5-fluorouracil/ leucovorin, oxaliplatin (FOLFOX6), bevacizumab, and cetuximab in patients with metastatic colorectal cancer. FOLFOX6 has proven to be a safe and effective regimen in firs...
United States
NCT00286130
Phase 2
Completed
150 patients
In Patients with metastatic colorectal cancer the following treatments first-line Folfiri+Cetuximab first-line Folfox6 + Cetuximab will be concerning efficacy and safety.
The trial compares Folfiri + Cetuximab and Folfox6 + Cetuximab concerning effi...
Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Hungary, Israel, Portugal, Roma
NCT00138177
Phase 1
Completed
54 patients
This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable colorectal cancer or ...
United States
NCT00449137
Phase 1
Completed
13 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Arsenic trioxide may help fluorouracil and leucovorin...
United States
NCT00138060
Phase 4
Completed
71 patients
Medications:
5-Fluorouracil
Irinotecan
This study intends to optimize a fluorouracil/irinotecan chemotherapy regimen by the identification of individual thymidylate synthase (TS) and UDP-glucuronosyltransferase 1 (UGT1A1) polymorphisms before the first administration.
The results of this...
France
NCT02582970
Phase 4
Completed
40 patients
This expanded access study will assess the efficacy and safety of intravenous (IV) bevacizumab in combination with chemotherapy regimens as first-line treatment of metastatic cancer of the colon or rectum. The anticipated median time on study treatme...
Taiwan
NCT00110721
Phase 2
Completed
20 patients
Medications:
5-Fluorouracil
Gm-ct-01
This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients. In this Phase II study, patients with colon ca...
United States, Israel
NCT00145314
Phase 3
Completed
571 patients
The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®) in first-line...
Norway
NCT00199797
Phase 1
Completed
20 patients
Although treatment for metastatic colorectal cancer has improved significantly over the recent years, it still remains a significant health problem representing the leading cancer by incidence in the United States of America. In the search for new th...
Germany, Switzerland
NCT00118261
Phase 1
Completed
17 patients
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, e...
United States
NCT00559676
Phase 4
Completed
200 patients
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers. It may also help doctors predict how patients will respond ...
France
NCT00645710
Phase 1
Completed
16 patients
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Hepatic arterial infusion uses a cathet...
United States
NCT00202787
Phase 2
Completed
136 patients
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with CRC and non-resectable hepatic metastases
Spain
NCT00116506
Phase 2
Completed
35 patients
Despite recent advances, most patients with advanced colorectal cancer continue to have a poor prognosis. 5-FU, leucovorin, oxaliplatin and bevacizumab is a standard treatment option for patients with stage IV colorectal cancer. Fluorouracil (5-FU), ...
United States
NCT00354978
Phase 2
Completed
49 patients
Objectives:
1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI \[folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as first line treatment....
United States
NCT00103298
Phase 2
Completed
30 patients
RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (c...
United States
NCT00101894
Phase 1
Completed
119 patients
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.
NCT00056030
Phase 2
Completed
73 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them wi...
United States
NCT00153998
Phase 2
Completed
135 patients
General Objectives:
* To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection
* To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chem...
Austria, Germany
NCT00100841
Phase 2
Completed
66 patients
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. So...
United States
NCT00096278
Phase 3
Completed
2,710 patients
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who have undergone surger...
United States
NCT00098982
Phase 1
Completed
16 patients
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor...
Italy, Switzerland, United Kingdom
NCT00286000
Phase 2
Completed
106 patients
A multicentre phase II study to evaluate the results of high dose simplified folfiri in advanced colorectal cancer
Belgium
NCT00154102
Phase 3
Completed
1,221 patients
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving combination ...
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Czechia, Finland, France, Germany,
NCT00208260
Phase 2
Completed
124 patients
Randomized, open label, multicentre phase II trial followed by phase III comparing overall survival after having selected the best experimental arm.
France
NCT00070122
Phase 3
Active
2,200 patients
Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in...
United States
NCT00262808
Phase 2
Completed
50 patients
RATIONALE: Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy or kill tumor cells. Drugs used in ch...
United States
NCT00085163
Phase 3
Completed
Medications:
5-Fluorouracil
Celecoxib
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their...
Austria, Belgium, Netherlands
NCT00084773
Not Applicable
Completed
28 patients
Medications:
5-Fluorouracil
Cetuximab
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as fluorouracil work in different ways to stop tu...
United States
NCT00080951
Phase 2
Completed
14 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPO...
NCT00081289
Phase 2
Completed
146 patients
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemoradiotherapy (combining chemotherapy with radiation ther...
United States
NCT00079274
Phase 3
Completed
3,397 patients
This randomized phase III trial was originally designed to compare three different combination chemotherapy regimens to see how well they work. As of September 1, 2004, the study was expanded to a total of 6 arms (the original 3 arms (A, B, C) and 3 ...
United States, Canada, Puerto Rico
NCT00280761
Not Applicable
Completed
47 patients
Medications:
5-Fluorouracil
Capecitabine
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to...
United States
NCT00068692
Phase 3
Completed
225 patients
This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage II or stage III rect...
United States
NCT00070213
Phase 3
Completed
460 patients
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, capecitabine, and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is no...
United Kingdom
NCT00166465
Phase 1
Completed
200 patients
Phase I: The primary objective of the Phase 1 portion of this study is to determine the Maximum tolerated dose and the recommended Phase 2 dose of ALIMTA plus oxaliplatin when given with folate and vitamin B-12 supplementation in the treatment of pat...
United States
NCT00063960
Phase 2
Completed
94 patients
RATIONALE: Drugs used in chemotherapy such as floxuridine and irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Hepatic arterial infusion uses a catheter to deliver chemotherapy directly to the liver. Combin...
United States
NCT00066846
Phase 2
Completed
Medications:
5-Fluorouracil
Bevacizumab
RATIONALE: Bevacizumab may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as fluorouracil and leucovorin use different ways to stop tumor cells from dividing so they stop growi...
United States
NCT00068744
Phase 2
Active
88 patients
Medications:
5-Fluorouracil
Cisplatin
RATIONALE: Drugs used in chemotherapy, such as mitomycin, fluorouracil, and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is no...
Belgium, Egypt, France, Germany, Italy, Netherlands, Serbia
NCT00303771
Phase 3
Completed
282 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination c...
France
NCT00060411
Phase 1
Completed
24 patients
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others fi...
United States
NCT01524094
Phase 3
Completed
49 patients
Medications:
5-Fluorouracil
The purpose of this study is to see if there is a difference in survival between two different treatment strategies for colorectal peritoneal surface disease. The control arm administered the currently considered standard treatment which is palliativ...
Sweden
NCT00064181
Phase 3
Completed
86 patients
RATIONALE: Drugs used in chemotherapy such as irinotecan, capecitabine, leucovorin, and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of colorectal cancer by stopping bloo...
Belgium, Egypt, Germany, Hungary, Israel
NCT00062426
Phase 3
Completed
375 patients
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different co...
United States
NCT00280176
Phase 1
Completed
11 patients
Medications:
5-Fluorouracil
Bortezomib
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tu...
United States
NCT00061815
Phase 3
Completed
102 patients
The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuxima...
United States
NCT00054977
Phase 1
Completed
40 patients
Medications:
5-Fluorouracil
Gm-ct-01
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with t...
United States
NCT00101686
Phase 3
Completed
547 patients
This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral). In the second period of study it compares FOLFIRI \[a chemotherapy regime that...
United States, Australia, Canada, New Zealand
NCT00059930
Phase 1
Completed
38 patients
The purpose of this study is to find the highest dose that can be given safely to people who have had liver disease resected. This is a Phase I study. The goal of a phase I study is to find a safe dose range based on side effects. The drugs that will...
United States
NCT00055822
Phase 1
Completed
16 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Oblimersen may increase the effectiveness of chemotherapy by making tumor ...
United States
NCT00052585
Phase 2
Active
50 patients
Medications:
5-Fluorouracil
Gefitinib
Phase II trial to study the effectiveness of combining gefitinib with fluorouracil, leucovorin, and irinotecan in treating patients who have advanced or recurrent colorectal cancer. Biological therapies such as gefitinib may stop the growth of tumor ...
United States
NCT00052559
Phase 1
Completed
32 patients
Medications:
5-Fluorouracil
Bevacizumab
This phase I trial is studying the side effects and best dose of bevacizumab when given together with fluorouracil and external-beam radiation therapy in treating patients with stage II or stage III rectal cancer. Monoclonal antibodies, such as bevac...
United States
NCT00049101
Phase 1
Completed
50 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with com...
United States
NCT00066274
Phase 2
Completed
80 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying combina...
France
NCT00268398
Phase 3
Completed
284 patients
PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with colorectal cancer and resectable metastases.
France
NCT00111761
Phase 2
Completed
43 patients
The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.
NCT00336960
Phase 2
Completed
24 patients
Medications:
5-Fluorouracil
Celecoxib
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tum...
United States
NCT00040391
Phase 2
Active
The study will combine a new investigational drug with standard anti-cancer drugs for the treatment of advanced colorectal cancer. The standard and approved treatment for colorectal cancer is to undergo chemotherapy with a combination of irinotecan (...
United States
NCT00043004
Phase 2
Active
119 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to gro...
Austria, Belgium, Egypt, France, Germany, Hungary, Italy, Netherlands, Sweden, United Kingdom
NCT00037180
Phase 2
Completed
212 patients
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approv...
United States
NCT00126256
Phase 3
Completed
570 patients
The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy. Several effective drugs are currently available and can be administered either sequentially or in combination. Most patients receive 2 or 3 lines of chemotherap...
France
NCT00039208
Phase 2
Completed
186 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at the time of day that allows for the best drug response may allow the doctor to give higher doses of chemotherapy d...
Belgium, France, Italy, Portugal
NCT00026234
Phase 2
Completed
75 patients
Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they ...
United States
NCT00023868
Phase 3
Completed
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. Chemoembolization kills tumor cell...
United States
NCT00030342
Phase 1
Completed
60 patients
Medications:
5-Fluorouracil
Sargramostim
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining biological th...
United States
NCT01219920
Phase 3
Completed
244 patients
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of response rate to conventional chemotherapy with the FOLFIRI regimen as first-line treatment of metastatic col...
Italy
NCT00026364
Phase 1
Completed
22 patients
Medications:
5-Fluorouracil
Gefitinib
Phase I trial to study the effectiveness of ZD 1839 combined with irinotecan, leucovorin, and fluorouracil in treating patients who have locally advanced, locally recurrent, or metastatic colorectal cancer. Biological therapies such as ZD 1839 may in...
United States
NCT00025337
Phase 3
Completed
880 patients
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been previously treated. Drugs used in chemotherapy use di...
United States
NCT00025142
Phase 2
Completed
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining mo...
United States
NCT00023751
Phase 2
Completed
320 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining surgery with chemotherapy and radiation therapy may kil...
United States, Canada, Puerto Rico
NCT00016198
Phase 2
Completed
200 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combinin...
United States
NCT00016978
Phase 2
Completed
40 patients
Phase II trial to study the effectiveness of combining oxaliplatin, fluorouracil and leucovorin in treating patients who have metastatic colorectal cancer that has been previously treated with irinotecan. Drugs used in chemotherapy use different ways...
United States, Canada
NCT00016952
Phase 2
Completed
19 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
PURPOSE: Phase II trial to compare the effectiveness of eit...
United States, Canada
NCT00020501
Phase 3
Completed
168 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. It is not yet known which chemotherapy r...
United States
NCT00025090
Phase 3
Completed
600 patients
Medications:
5-Fluorouracil
Cisplatin
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor c...
United Kingdom
NCT00155558
Phase 1
Completed
16 patients
Medications:
5-Fluorouracil
Leucovorin
To determine the maximum tolerated dose and dose limiting toxicity of 5-FU and leucovorin with novel 48-hour infusion schedule, and to collect toxicity profile at different dose level of 5-FU/LV 48-hour infusion.
Taiwan
NCT00016133
Phase 1
Completed
30 patients
Medications:
5-Fluorouracil
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. C...
United States
NCT00176774
Phase 2
Completed
24 patients
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combinatio...
United States
NCT00006366
Phase 2
Completed
100 patients
Medications:
5-Fluorouracil
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of radiation therapy plus chemo...
United States, Canada
NCT00020917
Phase 2
Completed
20 patients
Medications:
5-Fluorouracil
Cetuximab
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing s...
United States
NCT00026273
Phase 3
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill more tumor cells.
PURPOSE: Randomized phase III trial to comp...
Austria, Belgium, Egypt, France, Germany, Italy, Portugal, Spain, Switzerland, United Kingdom
NCT00006786
Phase 2
Completed
75 patients
Medications:
5-Fluorouracil
Bevacizumab
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bevacizumab may stop the growth of colorectal cancer by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the ef...
United States, Puerto Rico, South Africa
NCT00695201
Phase 1
Completed
52 patients
The purpose of this study is to see how well patients tolerate the side effects of treatment with Floxuridine, Oxaliplatin and Irinotecan. We also want to know if these methods used together are a useful way of treating cancer. We have studied these ...
United States
NCT00008294
Phase 1
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cryosurgery kills cancer cells by freezing them. Combining more than one chemotherapy drug with cryosurgery and giving drugs in di...
United States
NCT00006094
Phase 1
Completed
24 patients
Medications:
5-Fluorouracil
Oxaliplatin
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, radiation therapy, and surgery may be a more effecti...
United States
NCT00006103
Phase 3
Completed
400 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if the effectiveness of irinotecan combined with fluorouracil in treating colorectal cancer varies depending o...
NCT00008060
Phase 3
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effe...
United Kingdom
NCT00006015
Phase 2
Completed
26 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them ...
United States
NCT00209625
Phase 1
Completed
23 patients
We performed a phase I/II study of CPT-11/5FU/l-LV in advanced colorectal cancer, to determine the optimal dose of CPT-11 and to estimate the safety and efficacy of this regimen
Japan
NCT00004931
Phase 3
Completed
2,472 patients
Medications:
5-Fluorouracil
Oxaliplatin
Randomized phase III trial to compare the effectiveness of fluorouracil plus leucovorin with or without oxaliplatin in treating patients who have stage II or stage III colon cancer. Drugs used in chemotherapy use different ways to stop tumor cells fr...
United States
NCT00006037
Phase 2
Completed
18 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known if chemotherapy is more e...
United States
NCT00005036
Phase 3
Completed
560 patients
Medications:
5-Fluorouracil
Oxaliplatin
Randomized phase III trial to compare the effectiveness of irinotecan with that of combination chemotherapy in treating patients who have advanced colorectal cancer that has not responded to previous treatment. Drugs used in chemotherapy use differen...
United States
NCT00004252
Phase 3
Completed
710 patients
Medications:
5-Fluorouracil
Semaxanib
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known whether chemotherapy is m...
United States
NCT00005050
Phase 1
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining enilura...
United States
NCT00005944
Phase 2
Completed
152 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiv...
Belgium, France
NCT00004885
Phase 3
Completed
430 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether fluorouracil and leucovorin plus irinotecan is more effective than fluorouracil and leucovorin alone f...
Austria, Belgium, Egypt, France, Germany, Italy, Netherlands, Russia, South Africa
NCT00003835
Phase 3
Completed
1,260 patients
Medications:
5-Fluorouracil
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for stage III colon ...
United States
NCT00003799
Phase 1
Completed
20 patients
Medications:
5-Fluorouracil
Oxaliplatin
Phase I trial to study the effectiveness of radiation therapy plus chemotherapy followed by surgery and additional chemotherapy in treating patients who have advanced nonmetastatic primary cancer of the rectum. Drugs used in chemotherapy use differen...
United States
NCT00006050
Phase 2
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of liver perfusion u...
France
NCT00003873
Phase 3
Completed
950 patients
Medications:
5-Fluorouracil
Eniluracil
Randomized phase III trial to compare the effectiveness of fluorouracil given by infusion with that of fluorouracil plus eniluracil given by mouth in treating patients who have metastatic, recurrent, or residual advanced colorectal cancer. Drugs used...
United States
NCT00019760
Phase 2
Completed
50 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the ef...
United States
NCT00004150
Phase 3
Completed
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective for colon cancer.
PURPOSE: This randomized phase III trial is st...
Belgium, France, Germany, Netherlands, Serbia, Spain
NCT00003834
Phase 2
Completed
44 patients
Medications:
5-Fluorouracil
Oxaliplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemoth...
United States, Canada
NCT00003652
Phase 3
Completed
350 patients
Medications:
5-Fluorouracil
Cisplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor...
France
NCT00004102
Phase 2
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Leucovorin may increase the effectiveness of fluorouracil by making tumor ...
United States
NCT00009737
Phase 3
Completed
1,987 patients
This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer. Patients will be randomized to receive either Xeloda 1250mg/m2 po bid on ...
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Germany, Israel, Italy, Portu
NCT00003596
Phase 3
Completed
682 patients
Medications:
5-Fluorouracil
Cisplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known wheth...
United States, South Africa
NCT00003594
Phase 3
Completed
1,691 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is most effe...
United States, Canada, Puerto Rico, South Africa
NCT00004005
Phase 2
Completed
12 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining ...
United States
NCT00003753
Phase 2
Completed
RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die. Hepatic arterial infusion uses a catheter to deliver chemotherapy directly to...
United States
NCT00004142
Phase 2
Completed
40 patients
RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy delivered directly into the blood vessels of t...
United States
NCT00019513
Phase 1
Completed
108 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining gemcitabin...
United States
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
NCT00005979
Phase 3
Completed
400 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if combination chemotherapy is more effective with or ...
France
NCT00003543
Phase 1
Completed
18 patients
RATIONALE: Monoclonal antibodies can find and locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they st...
United States
NCT00003254
Phase 2
Completed
75 patients
Medications:
5-Fluorouracil
Ethynyluracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Ethynyluracil may help fluorouracil kill more cancer cells by making tumor cells more sensitive to the drug.
PURPOSE: Phase II tr...
United States
NCT00003287
Phase 3
Completed
554 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effe...
Austria, Belgium, Canada, France, Germany, Greece, Italy, Norway, Portugal
NCT00003422
Phase 3
Completed
1,800 patients
Medications:
5-Fluorouracil
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving radiation therapy before surge...
Canada, United Kingdom
NCT00003446
Phase 2
Completed
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of trimetrexate glucur...
Argentina
NCT00309517
Phase 3
Active
700 patients
Medications:
5-Fluorouracil
Leucovorin
This clinical investigation examined the influence of preoperative radiotherapy in combination with postoperative 5-fluorouracil + leucovorin chemotherapy vs. 5-fluorouracil + leucovorin + MAb 17-1A chemo-immunotherapy on patients' local recurrence r...
Austria
NCT00001576
Phase 1
Completed
28 patients
Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan. Postoperatively, patients will be treated with hepatic arterial infusion...
United States
NCT00002796
Phase 1
Active
46 patients
Medications:
5-Fluorouracil
Indomethacin
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon-gamma may interfere with the growth of tumor cells and slow the growth of the tumor. Combining more than one drug with interferon-...
United States
NCT00005049
Phase 2
Completed
45 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them by intraperitoneal infusion may kill more tumor cells.
PURPOSE: Phase II trial to st...
United States
NCT00378716
Phase 3
Completed
1,608 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug is a way to kill more tumor cells.
PURPOSE: Randomized phase III trial to determine the effectivenes...
NCT00021398
Phase 2
Completed
23 patients
Medications:
5-Fluorouracil
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy and chemotherapy may shrink the tumor...
United States
NCT00002716
Phase 3
Completed
135 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective for meta...
United States, Australia, Peru, Puerto Rico
NCT00002828
Phase 1
Completed
Medications:
5-Fluorouracil
Raltitrexed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of raltitrexed and fluo...
United States
NCT00002593
Phase 3
Completed
1,135 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more cancer cells.
PURPOSE: Randomized phase III trial t...
United States, Canada, Puerto Rico, South Africa
NCT00002842
Phase 2
Completed
49 patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
PURPOSE: Phase II trial to study the e...
United States
NCT00002551
Phase 3
Completed
1,917 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment regimen is more effective for...
United States, Canada, South Africa
NCT00309543
Phase 3
Completed
636 patients
Medications:
5-Fluorouracil
Leucovorin
This clinical investigation examined the influence of cytostatic chemotherapy with 5-fluorouracil, modulated by biologically active leucovorin, on patients' survival time following surgery for colon carcinoma Stage II.
Austria
NCT00002525
Phase 3
Completed
859 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known if surgery is more ...
United States
NCT00296608
Phase 3
Completed
762 patients
Medications:
5-Fluorouracil
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from ...
NCT00002523
Phase 3
Completed
1,011 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining radiation therapy and surgery with chemotherapy ma...
Belgium, France, Germany, Israel, Netherlands, Poland, Serbia, Spain, Switzerland, Turkey (Türkiye)
NCT00309530
Phase 3
Completed
598 patients
This clinical investigation examined the effectivity 5-fluorouracil, of adding levamisol or interferon to 5-fluorouracil, and of a 5-fluorouracil/levamisol/interferon triple combination, in terms of recurrence-free and overall survival in curatively ...
Austria
NCT00425152
Phase 3
Completed
2,151 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Leucovorin may help fluorouracil kill more tumor cells. Biological t...
NCT00427310
Phase 3
Completed
1,158 patients
Medications:
5-Fluorouracil
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving fluorouracil into the liver is mo...
NCT00427570
Phase 3
Completed
Medications:
5-Fluorouracil
Semustine
RATIONALE: Drugs used in chemotherapy, such as vincristine, fluorouracil, and semustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as BCG, may s...